U.S. patent application number 14/750439 was filed with the patent office on 2015-10-15 for macrocyclic picolinamides as fungicides.
The applicant listed for this patent is DOW AGROSCIENCES LLC. Invention is credited to Fangzheng Li, Kevin G. Meyer, Benjamin Nugent, W. John Owen, James M. Renga, Nick X. Wang, Chenglin Yao.
Application Number | 20150289508 14/750439 |
Document ID | / |
Family ID | 49513004 |
Filed Date | 2015-10-15 |
United States Patent
Application |
20150289508 |
Kind Code |
A1 |
Meyer; Kevin G. ; et
al. |
October 15, 2015 |
MACROCYCLIC PICOLINAMIDES AS FUNGICIDES
Abstract
The disclosure relates to macrocyclic picolinamides of Formula I
and their use as fungicides. ##STR00001##
Inventors: |
Meyer; Kevin G.;
(Zionsville, IN) ; Renga; James M.; (Spokane,
WA) ; Nugent; Benjamin; (Brownsburg, IN) ; Li;
Fangzheng; (Carmel, IN) ; Owen; W. John;
(Carmel, IN) ; Yao; Chenglin; (Westfield, IN)
; Wang; Nick X.; (Carmel, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DOW AGROSCIENCES LLC |
Indianapolis |
IN |
US |
|
|
Family ID: |
49513004 |
Appl. No.: |
14/750439 |
Filed: |
June 25, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13887726 |
May 6, 2013 |
|
|
|
14750439 |
|
|
|
|
61643623 |
May 7, 2012 |
|
|
|
Current U.S.
Class: |
514/256 ;
514/333; 514/336; 514/338; 544/333; 546/256; 546/281.7;
546/283.7 |
Current CPC
Class: |
A01N 43/40 20130101;
A01N 43/54 20130101; C07D 405/14 20130101; A01N 43/647 20130101;
C07D 405/12 20130101 |
International
Class: |
A01N 43/40 20060101
A01N043/40; A01N 43/647 20060101 A01N043/647; A01N 43/54 20060101
A01N043/54; C07D 405/12 20060101 C07D405/12; C07D 405/14 20060101
C07D405/14 |
Claims
1. A compound of Formula I: ##STR00116## wherein, R.sub.1 is H,
--C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3; R.sub.2 is H, halogen,
alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio or
heteroarylthio each substituted with 0, 1 or multiple R.sub.5,
--CH.sub.2R.sub.4, --CH.sub.2OC(O)R.sub.4, --C(O)OR.sub.4,
--CH.sub.2OS(O).sub.2R.sub.4, or --CH.sub.2OR.sub.4; R.sub.3 is
alkyl or alkoxy, substituted with 0, 1, or multiple R.sub.5;
R.sub.4 is H, alkyl, alkenyl, aryl, arylalkyl, or heterocyclyl,
each substituted with 0, 1 or multiple R.sub.5; R.sub.5 is alkyl,
alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano,
aryl or heterocyclyl, each substituted with 0, 1 or multiple
R.sub.6; and R.sub.6 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl.
2. The compound according to claim 1, wherein: R.sub.1 is H,
--C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3; R.sub.2 is alkyl,
alkenyl, or aryl, each substituted with 0, 1 or multiple R.sub.5;
R.sub.3 is alkyl or alkoxy, substituted with 0, 1, or multiple
R.sub.5; R.sub.5 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl, each
substituted with 0, 1 or multiple R.sub.6; and R.sub.6 is alkyl,
alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano,
aryl or heterocyclyl.
3. A compound according to claim 3, wherein: R.sub.1 is H,
--C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3; R.sub.2 is alkyl,
alkenyl, or aryl, each substituted with 0, 1 or multiple R.sub.5;
R.sub.3 is alkyl or alkoxy, substituted with 0, 1, or multiple
R.sub.5; and R.sub.5 is alkyl, halo, haloalkyl, or aryl.
4. A compound according to claim 3, wherein: R.sub.1 is H,
--C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3; R.sub.2 is alkyl,
alkenyl, or aryl, each substituted with 0, 1 or multiple R.sub.5;
R.sub.3 is alkyl; and R.sub.5 is alkyl, halo, haloalkyl, or
aryl.
5. A composition for the control of a fungal pathogen, including
the compound of Formula I ##STR00117## wherein, R.sub.1 is H,
--C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3; R.sub.2 is H, halogen,
alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio or
heteroarylthio each substituted with 0, 1 or multiple R.sub.5,
--CH.sub.2R.sub.4, --CH.sub.2OC(O)R.sub.4, --C(O)OR.sub.4,
--CH.sub.2OS(O).sub.2R.sub.4, or --CH.sub.2OR.sub.4; R.sub.3 is
alkyl or alkoxy, substituted with 0, 1, or multiple R.sub.5;
R.sub.4 is H, alkyl, alkenyl, aryl, arylalkyl, or heterocyclyl,
each substituted with 0, 1 or multiple R.sub.5; R.sub.5 is alkyl,
alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano,
aryl or heterocyclyl, each substituted with 0, 1 or multiple
R.sub.6; and R.sub.6 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl, and at least
one phytologically acceptable carrier and/or at least one
agriculturally active ingredient selected from the group consisting
of pesticides, fungicides, insecticides, nematocides, miticides,
arthropodicides, bactericides and combinations thereof.
6. A method for treating a plant, comprising the steps of: applying
an amount of at least one of the compounds of Formula I
##STR00118## wherein, R.sub.1 is H, --C(O)R.sub.3, or
--CH.sub.2OC(O)R.sub.3; R.sub.2 is H, halogen, alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, alkylthio, arylthio or heteroarylthio
each substituted with 0, 1 or multiple R.sub.5, --CH.sub.2R.sub.4,
--CH.sub.2OC(O)R.sub.4, --C(O)OR.sub.4,
--CH.sub.2OS(O).sub.2R.sub.4, or --CH.sub.2OR.sub.4; R.sub.3 is
alkyl or alkoxy, substituted with 0, 1, or multiple R.sub.5;
R.sub.4 is H, alkyl, alkenyl, aryl, arylalkyl, or heterocyclyl,
each substituted with 0, 1 or multiple R.sub.5; R.sub.5 is alkyl,
alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano,
aryl or heterocyclyl, each substituted with 0, 1 or multiple
R.sub.6; and R.sub.6 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl, to at least
one portion of a plant, an area adjacent to a plant, and/or soil
adapted to support growth of a plant, wherein said amount is
effective for the control of at least one plant pathogen.
7. The compositions according to claim 6, wherein the effective
amount of the compound is effective against at least one plant
pathogen selected from the group consisting of: Leaf Blotch of
Wheat (Mycosphaerella graminicola; anamorph: Septoria tritici),
Wheat Brown Rust (Puccinia triticina), Stripe Rust (Puccinia
striiformis), and Black Sigatoka (Mycosphaerella fujiensis).
8. The composition according to claim 7, wherein the plant pathogen
is at least one organism selected from the group consisting of
(Septoria tritici) and (Puccinia triticina).
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Patent Application Ser. No. 61/643,623 filed May 7, 2012, which is
expressly incorporated by reference herein.
BACKGROUND & SUMMARY
[0002] Fungicides are compounds, of natural or synthetic origin,
which act to protect and/or cure plants against damage caused by
agriculturally relevant fungi. Generally, no single fungicide is
useful in all situations. Consequently, research is ongoing to
produce fungicides that may have better performance, are easier to
use, and cost less.
[0003] The present disclosure relates to macrocyclic picolinamides
and their use as fungicides. The compounds of the present
disclosure may offer protection against ascomycetes,
basidiomycetes, deuteromycetes and oomycetes.
[0004] One embodiment of the present disclosure may include
compounds of Formula I:
##STR00002##
[0005] R.sub.1 is H, --C(O)R.sub.3, or --CH.sub.2OC(O)R.sub.3;
[0006] R.sub.2 is H, halogen, alkyl, alkenyl, alkynyl, aryl,
heterocyclyl, alkylthio, arylthio or heteroarylthio each
substituted with 0, 1 or multiple R.sub.5, --CH.sub.2R.sub.4,
--CH.sub.2OC(O)R.sub.4, --C(O)OR.sub.4,
--CH.sub.2OS(O).sub.2R.sub.4, or --CH.sub.2OR.sub.4;
[0007] R.sub.3 is alkyl or alkoxy, substituted with 0, 1, or
multiple R.sub.5;
[0008] R.sub.4 is H, alkyl, alkenyl, aryl, arylalkyl, or
heterocyclyl, each substituted with 0, 1 or multiple R.sub.5;
[0009] R.sub.5 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl, each
substituted with 0, 1 or multiple R.sub.6; and
[0010] R.sub.6 is alkyl, alkenyl, halo, haloalkyl, alkoxy,
haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl.
[0011] Another embodiment of the present disclosure may include a
fungicidal composition for the control or prevention of fungal
attack comprising the compounds described above and a
phytologically acceptable carrier material.
[0012] Yet another embodiment of the present disclosure may include
a method for the control or prevention of fungal attack on a plant,
the method including the steps of applying a fungicidally effective
amount of one or more of the compounds described above to at least
one of the fungus, the plant, and an area adjacent to the
plant.
[0013] It will be understood by the those skilled in the art that
the following terms may include generic "R"-groups within their
definitions, e.g., "the term alkoxy refers to an --OR substituent".
It is also understood that within the definitions for the following
terms, these "R" groups are included for illustration purposes and
should not be construed as limiting or being limited by
substitutions about Formula I.
[0014] The term "alkyl" refers to a branched, unbranched, or cyclic
saturated carbon chain, including, but not limited to, methyl,
ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl, pentyl,
hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the
like.
[0015] The term "alkenyl" refers to a branched, unbranched or
cyclic carbon chain containing one or more double bonds including,
but not limited to, ethenyl, propenyl, butenyl, isopropenyl,
isobutenyl, cyclohexenyl, and the like.
[0016] The term "alkynyl" refers to a branched or unbranched carbon
chain containing one or more triple bonds including, but not
limited to, propynyl, butyryl and the like.
[0017] The term "aryl" refers to any aromatic, mono- or bi-cyclic,
containing 0 heteroatoms.
[0018] The term "heterocyclyl" refers to any aromatic or
non-aromatic ring, mono- or bi-cyclic, containing one or more
heteroatoms
[0019] The term "alkoxy" refers to an --OR substituent.
[0020] The term "alkoxycarbonyl" refers to a --C(O)--OR
substituent.
[0021] The term "alkylcarbonyl" refers to a --C(O)--R
substituent.
[0022] The term "alkylsulfonyl" refers to an --SO.sub.2--R
substituent.
[0023] The term "haloalkylsulfonyl" refers to an --SO.sub.2--R
substituent where R is fully or partially substituted with Cl, F,
I, or Br or any combination thereof
[0024] The term "alkylthio" refers to an --S--R substituent.
[0025] The term "haloalkylthio" refers to an alkylthio, which is
substituted with Cl, F, I, or Br or any combination thereof.
[0026] The term "alkylaminocarbonyl" refers to a --C(O)--N(H)--R
substituent.
[0027] The term "dialkylaminocarbonyl" refers to a --C(O)--NR.sub.2
substituent.
[0028] The term "alkylcycloalkylamino" refers to a cycloalkylamino
substituent that is substituted with an alkyl group.
[0029] The term "trialkylsilyl" refers to --Si(R).sub.3.
[0030] The term "cyano" refers to a --C.ident.N substituent.
[0031] The term "hydroxyl" refers to an --OH substituent.
[0032] The term "amino" refers to a --NH.sub.2 substituent.
[0033] The term "alkylamino" refers to a --N(H)--R substituent.
[0034] The term "dialkylamino" refers to a --N(R).sub.2
substituent.
[0035] The term "alkoxyalkoxy" refers to
--O(CH.sub.2)--O(CH.sub.2)-- where n is an integer from 1-3.
[0036] The term "alkoxyalkyl" refers to an alkoxy substitution on
an alkyl.
[0037] The term "arylalkoxy" refers to --O(CH.sub.2)--Ar where n is
an integer selected from the list 1, 2, 3, 4, 5, or 6.
[0038] The term "arylalkyl" refers to --(CH.sub.2)--Ar where n is
an integer selected from the list 1, 2, 3, 4, 5, or 6.
[0039] The term "haloalkoxyalkyl" refers to an alkoxy substitution
on an alkyl which may be partially substituted with halogen
atoms.
[0040] The term "hydroxyalkyl" refers to an alkyl which is
substituted with a hydroxyl group.
[0041] The term "haloalkoxy" refers to an --OR--X substituent,
wherein X is Cl, F, Br, or I, or any combination thereof.
[0042] The term "haloalkyl" refers to an alkyl, which is
substituted with Cl, F, I, or Br or any combination thereof.
[0043] The term "haloalkenyl" refers to an alkenyl, which is
substituted with Cl, F, I, or Br or any combination thereof.
[0044] The term "haloalkynyl" refers to an alkynyl which is
substituted with Cl, F, I, or Br or any combination thereof.
[0045] The term "halogen" or "halo" refers to one or more halogen
atoms, defined as F, Cl, Br, and I.
[0046] The term "hydroxycarbonyl" refers to a --C(O)--OH
substituent.
[0047] The term "nitro" refers to a --NO.sub.2 substituent.
[0048] Throughout the disclosure, reference to the compounds of
Formula I is read as also including diastereomers, enantiomers, and
mixtures thereof. In another embodiment, Formula (I) is read as
also including salts or hydrates thereof. Exemplary salts include,
but are not limited to: hydrochloride, hydrobromide, and
hydroiodide.
[0049] It is also understood by those skilled in the art that
additional substitution is allowable, unless otherwise noted, as
long as the rules of chemical bonding and strain energy are
satisfied and the product still exhibits fungicidal activity.
[0050] Another embodiment of the present disclosure is a use of a
compound of Formula I, for protection of a plant against attack by
a phytopathogenic organism or the treatment of a plant infested by
a phytopathogenic organism, comprising the application of a
compound of Formula I, or a composition comprising the compound to
soil, a plant, a part of a plant, foliage, and/or roots.
[0051] Additionally, another embodiment of the present disclosure
is a composition useful for protecting a plant against attack by a
phytopathogenic organism and/or treatment of a plant infested by a
phytopathogenic organism comprising a compound of Formula I and a
phytologically acceptable carrier material.
DETAILED DESCRIPTION
[0052] The compounds of the present disclosure may be applied by
any of a variety of known techniques, either as the compounds or as
formulations comprising the compounds. For example, the compounds
may be applied to the roots or foliage of plants for the control of
various fungi, without damaging the commercial value of the plants.
The materials may be applied in the form of any of the generally
used formulation types, for example, as solutions, dusts, wettable
powders, flowable concentrates, or emulsifiable concentrates.
[0053] In some embodiments, the compounds of the present disclosure
are applied in the form of a formulation, comprising one or more of
the compounds of Formula I with a phytologically acceptable
carrier. Concentrated formulations may be dispersed in water, or
other liquids, for application, or formulations may be dust-like or
granular, which may then be applied without further treatment. The
formulations can be prepared according to procedures that are
conventional in the agricultural chemical art.
[0054] The present disclosure contemplates all vehicles by which
one or more of the compounds may be formulated for delivery and use
as a fungicide. Typically, formulations are applied as aqueous
suspensions or emulsions. Such suspensions or emulsions may be
produced from water-soluble, water-suspendible, or emulsifiable
formulations which are solids, usually known as wettable powders;
or liquids, usually known as emulsifiable concentrates, aqueous
suspensions, or suspension concentrates. As will be readily
appreciated, any material to which these compounds may be added may
be used, provided it yields the desired utility without significant
interference with the activity of these compounds as antifungal
agents.
[0055] Wettable powders, which may be compacted to form
water-dispersible granules, comprise an intimate mixture of one or
more of the compounds of Formula I, an inert carrier and
surfactants. The concentration of the compound in the wettable
powder may be from about 10 percent to about 90 percent by weight
based on the total weight of the wettable powder, more preferably
about 25 weight percent to about 75 weight percent. In the
preparation of wettable powder formulations, the compounds may be
compounded with any finely divided solid, such as prophyllite,
talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite,
starch, casein, gluten, montmorillonite clays, diatomaceous earths,
purified silicates or the like. In such operations, the finely
divided carrier and surfactants are typically blended with the
compound(s) and milled.
[0056] Emulsifiable concentrates of the compounds of Formula I may
comprise a convenient concentration, such as from about 1 weight
percent to about 50 weight percent of the compound, in a suitable
liquid, based on the total weight of the concentrate. The compounds
may be dissolved in an inert carrier, which is either a
water-miscible solvent or a mixture of water-immiscible organic
solvents, and emulsifiers. The concentrates may be diluted with
water and oil to form spray mixtures in the form of oil-in-water
emulsions. Useful organic solvents include aromatics, especially
the high-boiling naphthalenic and olefinic portions of petroleum
such as heavy aromatic naphtha. Other organic solvents may also be
used, for example, terpenic solvents, including rosin derivatives,
aliphatic ketones, such as cyclohexanone, and complex alcohols,
such as 2-ethoxyethanol.
[0057] Emulsifiers which may be advantageously employed herein may
be readily determined by those skilled in the art and include
various nonionic, anionic, cationic and amphoteric emulsifiers, or
a blend of two or more emulsifiers. Examples of nonionic
emulsifiers useful in preparing the emulsifiable concentrates
include the polyalkylene glycol ethers and condensation products of
alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or
fatty acids with ethylene oxide, propylene oxides such as the
ethoxylated alkyl phenols and carboxylic esters solubilized with
the polyol or polyoxyalkylene. Cationic emulsifiers include
quaternary ammonium compounds and fatty amine salts. Anionic
emulsifiers include the oil-soluble salts (e.g., calcium) of
alkylaryl sulphonic acids, oil-soluble salts or sulfated polyglycol
ethers and appropriate salts of phosphated polyglycol ether.
[0058] Representative organic liquids which may be employed in
preparing the emulsifiable concentrates of the compounds of the
present disclosure are the aromatic liquids such as xylene, propyl
benzene fractions; or mixed naphthalene fractions, mineral oils,
substituted aromatic organic liquids such as dioctyl phthalate;
kerosene; dialkyl amides of various fatty acids, particularly the
dimethyl amides of fatty glycols and glycol derivatives such as the
n-butyl ether, ethyl ether or methyl ether of diethylene glycol,
the methyl ether of triethylene glycol, petroleum fractions or
hydrocarbons such as mineral oil, aromatic solvents, paraffinic
oils, and the like; vegetable oils such as soy bean oil, rape seed
oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn
oil, cotton seed oil, linseed oil, palm oil, peanut oil, safflower
oil, sesame oil, tung oil and the like; esters of the above
vegetable oils; and the like. Mixtures of two or more organic
liquids may also be employed in the preparation of the emulsifiable
concentrate. Organic liquids include xylene, and propyl benzene
fractions, with xylene being most preferred in some cases.
Surface-active dispersing agents are typically employed in liquid
formulations and in an amount of from 0.1 to 20 percent by weight
based on the combined weight of the dispersing agent with one or
more of the compounds. The formulations can also contain other
compatible additives, for example, plant growth regulators and
other biologically active compounds used in agriculture.
[0059] Aqueous suspensions comprise suspensions of one or more
water-insoluble compounds of Formula I, dispersed in an aqueous
vehicle at a concentration in the range from about 1 to about 50
weight percent, based on the total weight of the aqueous
suspension. Suspensions are prepared by finely grinding one or more
of the compounds, and vigorously mixing the ground material into a
vehicle comprised of water and surfactants chosen from the same
types discussed above. Other components, such as inorganic salts
and synthetic or natural gums, may also be added to increase the
density and viscosity of the aqueous vehicle.
[0060] The compounds of Formula I can also be applied as granular
formulations, which are particularly useful for applications to the
soil. Granular formulations generally contain from about 0.5 to
about 10 weight percent, based on the total weight of the granular
formulation of the compound(s), dispersed in an inert carrier which
consists entirely or in large part of coarsely divided inert
material such as attapulgite, bentonite, diatomite, clay or a
similar inexpensive substance. Such formulations are usually
prepared by dissolving the compounds in a suitable solvent and
applying it to a granular carrier which has been preformed to the
appropriate particle size, in the range of from about 0.5 to about
3 mm. A suitable solvent is a solvent in which the compound is
substantially or completely soluble. Such formulations may also be
prepared by making a dough or paste of the carrier and the compound
and solvent, and crushing and drying to obtain the desired granular
particle.
[0061] Dusts containing the compounds of Formula I may be prepared
by intimately mixing one or more of the compounds in powdered form
with a suitable dusty agricultural carrier, such as, for example,
kaolin clay, ground volcanic rock, and the like. Dusts can suitably
contain from about 1 to about 10 weight percent of the compounds,
based on the total weight of the dust.
[0062] The formulations may additionally contain adjuvant
surfactants to enhance deposition, wetting and penetration of the
compounds onto the target crop and organism. These adjuvant
surfactants may optionally be employed as a component of the
formulation or as a tank mix. The amount of adjuvant surfactant
will typically vary from 0.01 to 1.0 percent by volume, based on a
spray-volume of water, preferably 0.05 to 0.5 volume percent.
Suitable adjuvant surfactants include, but are not limited to
ethoxylated nonyl phenols, ethoxylated synthetic or natural
alcohols, salts of the esters or sulphosuccinic acids, ethoxylated
organosilicones, ethoxylated fatty amines, blends of surfactants
with mineral or vegetable oils, crop oil concentrate (mineral oil
(85%)+emulsifiers (15%)); nonylphenol ethoxylate;
benzylcocoalkyldimethyl quaternary ammonium salt; blend of
petroleum hydrocarbon, alkyl esters, organic acid, and anionic
surfactant; C.sub.9-C.sub.11 alkylpolyglycoside; phosphated alcohol
ethoxylate; natural primary alcohol (C.sub.12-C.sub.16) ethoxylate;
di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap;
nonylphenol ethoxylate+urea ammonium nitrate; emulsified methylated
seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow
amine ethoxylate (15 EO); PEG(400) dioleate-99. The formulations
may also include oil-in-water emulsions such as those disclosed in
U.S. patent application Ser. No. 11/495,228, the disclosure of
which is expressly incorporated by reference herein.
[0063] The formulations may optionally include combinations that
contain other pesticidal compounds. Such additional pesticidal
compounds may be fungicides, insecticides, herbicides, nematocides,
miticides, arthropodicides, bactericides or combinations thereof
that are compatible with the compounds of the present disclosure in
the medium selected for application, and not antagonistic to the
activity of the present compounds. Accordingly, in such
embodiments, the other pesticidal compound is employed as a
supplemental toxicant for the same or for a different pesticidal
use. The compounds of Formula I and the pesticidal compound in the
combination can generally be present in a weight ratio of from
1:100 to 100:1.
[0064] The compounds of the present disclosure may also be combined
with other fungicides to form fungicidal mixtures and synergistic
mixtures thereof. The fungicidal compounds of the present
disclosure are often applied in conjunction with one or more other
fungicides to control a wider variety of undesirable diseases. When
used in conjunction with other fungicide(s), the presently claimed
compounds may be formulated with the other fungicide(s), tank-mixed
with the other fungicide(s) or applied sequentially with the other
fungicide(s). Such other fungicides may include
2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol,
8-hydroxyquinoline sulfate, ametoctradin, amisulbrom, antimycin,
Ampelomyces quisqualis, azaconazole, azoxystrobin, Bacillus
subtilis, Bacillus subtilis strain QST713, benalaxyl, benomyl,
benthiavalicarb-isopropyl, benzylaminobenzene-sulfonate (BABS)
salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen,
blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole,
bupirimate, calcium polysulfide, captafol, captan, carbendazim,
carboxin, carpropamid, carvone, chlazafenone, chloroneb,
chlorothalonil, chlozolinate, Coniothyrium minitans, copper
hydroxide, copper octanoate, copper oxychloride, copper sulfate,
copper sulfate (tribasic), cuprous oxide, cyazofamid, cyflufenamid,
cymoxanil, cyproconazole, cyprodinil, dazomet, debacarb, diammonium
ethylenebis-(dithiocarbamate), dichlofluanid, dichlorophen,
diclocymet, diclomezine, dichloran, diethofencarb, difenoconazole,
difenzoquat ion, diflumetorim, dimethomorph, dimoxystrobin,
diniconazole, diniconazole-M, dinobuton, dinocap, diphenylamine,
dithianon, dodemorph, dodemorph acetate, dodine, dodine free base,
edifenphos, enestrobin, enestroburin, epoxiconazole, ethaboxam,
ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol,
fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil,
fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate,
fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil,
flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin,
fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil,
flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl,
fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, guazatine,
guazatine acetates, GY-81, hexachlorobenzene, hexaconazole,
hymexazol, imazalil, imazalil sulfate, imibenconazole,
iminoctadine, iminoctadine triacetate, iminoctadine
tris(albesilate), iodocarb, ipconazole, ipfenpyrazolone,
iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam,
isotianil, kasugamycin, kasugamycin hydrochloride hydrate,
kresoxim-methyl, laminarin, mancopper, mancozeb, mandipropamid,
maneb, mefenoxam, mepanipyrim, mepronil, meptyl-dinocap, mercuric
chloride, mercuric oxide, mercurous chloride, metalaxyl,
metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium,
metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate,
metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil,
nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic
acid (fatty acids), orysastrobin, oxadixyl, oxine-copper,
oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole,
pencycuron, penflufen, pentachlorophenol, pentachlorophenyl
laurate, penthiopyrad, phenylmercury acetate, phosphonic acid,
phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim,
potassium bicarbonate, potassium hydroxyquinoline sulfate,
probenazole, prochloraz, procymidone, propamocarb, propamocarb
hydrochloride, propiconazole, propineb, proquinazid,
prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin,
pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil,
pyriofenone, pyroquilon, quinoclamine, quinoxyfen, quintozene,
Reynoutria sachalinensis extract, sedaxane, silthiofam,
simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium
pentachlorophenoxide, spiroxamine, sulfur, SYP-Z048, tar oils,
tebuconazole, tebufloquin, tecnazene, tetraconazole, thiabendazole,
thifluzamide, thiophanate-methyl, thiram, tiadinil,
tolclofos-methyl, tolylfluanid, triadimefon, triadimenol,
triazoxide, tricyclazole, tridemorph, trifloxystrobin,
triflumizole, triforine, triticonazole, validamycin, valifenalate,
valiphenal, vinclozolin, zineb, ziram, zoxamide, Candida oleophila,
Fusarium oxysporum, Gliocladium spp., Phlebiopsis gigantea,
Streptomyces griseoviridis, Trichoderma spp.,
(RS)--N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide,
1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone
hydrate, 1-chloro-2,4-dinitronaphthalene, 1-chloro-2-nitropropane,
2-(2-heptadecyl-2-imidazolin-1-yl)ethanol,
2,3-dihydro-5-phenyl-1,4-dithi-ine 1,1,4,4-tetraoxide,
2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride,
2-methoxyethylmercury silicate,
3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-1-enyl)phenyl
thiocyanateme, ampropylfos, anilazine, azithiram, barium
polysulfide, Bayer 32394, benodanil, benquinox, bentaluron,
benzamacril; benzamacril-isobutyl, benzamorf, binapacryl,
bis(methylmercury) sulfate, bis(tributyltin) oxide, buthiobate,
cadmium calcium copper zinc chromate sulfate, carbamorph, CECA,
chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox,
climbazole, copper bis(3-phenylsalicylate), copper zinc chromate,
cufraneb, cupric hydrazinium sulfate, cuprobam, cyclafuramid,
cypendazole, cyprofuram, decafentin, dichlone, dichlozoline,
diclobutrazol, dimethirimol, dinocton, dinosulfon, dinoterbon,
dipyrithione, ditalimfos, dodicin, drazoxolon, EBP, ESBP,
etaconazole, etem, ethirim, fenaminosulf, fenapanil, fenitropan,
fluotrimazole, furcarbanil, furconazole, furconazole-cis,
furmecyclox, furophanate, glyodine, griseofulvin, halacrinate,
Hercules 3944, hexylthiofos, ICIA0858, isopamphos, isovaledione,
mebenil, mecarbinzid, metazoxolon, methfuroxam, methylmercury
dicyandiamide, metsulfovax, milneb, mucochloric anhydride,
myclozolin, N-3,5-dichlorophenyl-succinimide,
N-3-nitrophenylitaconimide, natamycin,
N-ethylmercurio-4-toluenesulfonanilide, nickel
bis(dimethyldithiocarbamate), OCH, phenylmercury
dimethyldithiocarbamate, phenylmercury nitrate, phosdiphen,
prothiocarb; prothiocarb hydrochloride, pyracarbolid, pyridinitril,
pyroxychlor, pyroxyfur, quinacetol; quinacetol sulfate, quinazamid,
quinconazole, rabenzazole, salicylanilide, SSF-109, sultropen,
tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate,
thioquinox, tioxymid, triamiphos, triarimol, triazbutil,
trichlamide, urbacid, zarilamid, and any combinations thereof.
[0065] Additionally, the compounds described herein may be combined
with other pesticides, including insecticides, nematocides,
miticides, arthropodicides, bactericides or combinations thereof
that are compatible with the compounds of the present disclosure in
the medium selected for application, and not antagonistic to the
activity of the present compounds to form pesticidal mixtures and
synergistic mixtures thereof. The fungicidal compounds of the
present disclosure may be applied in conjunction with one or more
other pesticides to control a wider variety of undesirable pests.
When used in conjunction with other pesticides, the presently
claimed compounds may be formulated with the other pesticide(s),
tank-mixed with the other pesticide(s) or applied sequentially with
the other pesticide(s). Typical insecticides include, but are not
limited to: 1,2-dichloropropane, abamectin, acephate, acetamiprid,
acethion, acetoprole, acrinathrin, acrylonitrile, alanycarb,
aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, allyxycarb,
alpha-cypermethrin, alpha-ecdysone, alpha-endosulfan, amidithion,
aminocarb, amiton, amiton oxalate, amitraz, anabasine, athidathion,
azadirachtin, azamethiphos, azinphos-ethyl, azinphos-methyl,
azothoate, barium hexafluorosilicate, barthrin, bendiocarb,
benfuracarb, bensultap, beta-cyfluthrin, beta-cypermethrin,
bifenthrin, bioallethrin, bioethanomethrin, biopermethrin,
bistrifluron, borax, boric acid, bromfenvinfos, bromocyclen,
bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin,
butacarb, butathiofos, butocarboxim, butonate, butoxycarboxim,
cadusafos, calcium arsenate, calcium polysulfide, camphechlor,
carbanolate, carbaryl, carbofuran, carbon disulfide, carbon
tetrachloride, carbophenothion, carbosulfan, cartap, cartap
hydrochloride, chlorantraniliprole, chlorbicyclen, chlordane,
chlordecone, chlordimeform, chlordimeform hydrochloride,
chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron,
chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos,
chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide,
cinerin I, cinerin II, cinerins, cismethrin, cloethocarb,
closantel, clothianidin, copper acetoarsenite, copper arsenate,
copper naphthenate, copper oleate, coumaphos, coumithoate,
crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos,
cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin,
cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cyromazine,
cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O,
demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl,
demeton-S, demeton-S-methyl, demeton-S-methylsulphon,
diafenthiuron, dialifos, diatomaceous earth, diazinon, dicapthon,
dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil,
dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan,
dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex,
dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan,
dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos,
d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium,
doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC,
empenthrin, endosulfan, endothion, endrin, EPN, epofenonane,
eprinomectin, esdepallethrine, esfenvalerate, etaphos,
ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl
formate, ethyl-DDD, ethylene dibromide, ethylene dichloride,
ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos,
fenazaflor, fenchlorphos, fenethacarb, fenfluthrin, fenitrothion,
fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin,
fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil,
flonicamid, flubendiamide, flucofuron, flucycloxuron,
flucythrinate, flufenerim, flufenoxuron, flufenprox, fluvalinate,
fonofos, formetanate, formetanate hydrochloride, formothion,
formparanate, formparanate hydrochloride, fosmethilan, fospirate,
fosthietan, furathiocarb, furethrin, gamma-cyhalothrin, gamma-HCH,
halfenprox, halofenozide, HCH, HEOD, heptachlor, heptenophos,
heterophos, hexaflumuron, HHDN, hydramethylnon, hydrogen cyanide,
hydroprene, hyquincarb, imidacloprid, imiprothrin, indoxacarb,
iodomethane, IPSP, isazofos, isobenzan, isocarbophos, isodrin,
isofenphos, isofenphos-methyl, isoprocarb, isoprothiolane,
isothioate, isoxathion, ivermectin, jasmolin I, jasmolin II,
jodfenphos, juvenile hormone I, juvenile hormone II, juvenile
hormone III, kelevan, kinoprene, lambda-cyhalothrin, lead arsenate,
lepimectin, leptophos, lindane, lirimfos, lufenuron, lythidathion,
malathion, malonoben, mazidox, mecarbam, mecarphon, menazon,
mephosfolan, mercurous chloride, mesulfenfos, metaflumizone,
methacrifos, methamidophos, methidathion, methiocarb,
methocrotophos, methomyl, methoprene, methoxychlor,
methoxyfenozide, methyl bromide, methyl isothiocyanate,
methylchloroform, methylene chloride, metofluthrin, metolcarb,
metoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin
oxime, mipafox, mirex, molosultap, monocrotophos, monomehypo,
monosultap, morphothion, moxidectin, naftalofos, naled,
naphthalene, nicotine, nifluridide, nitenpyram, nithiazine,
nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl,
oxydemeton-methyl, oxydeprofos, oxydisulfoton,
para-dichlorobenzene, parathion, parathion-methyl, penfluron,
pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate,
phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon,
phosphine, phoxim, phoxim-methyl, pirimetaphos, pirimicarb,
pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium
thiocyanate, pp'-DDT, prallethrin, precocene I, precocene II,
precocene III, primidophos, profenofos, profluralin, promacyl,
promecarb, propaphos, propetamphos, propoxur, prothidathion,
prothiofos, prothoate, protrifenbute, pyraclofos, pyrafluprole,
pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins,
pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon,
pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia,
quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin,
rotenone, ryania, sabadilla, schradan, selamectin, silafluofen,
silica gel, sodium arsenite, sodium fluoride, sodium
hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram,
spinosad, spiromesifen, spirotetramat, sulcofuron,
sulcofuron-sodium, sulfluramid, sulfotep, sulfoxaflor, sulfuryl
fluoride, sulprofos, tau-fluvalinate, tazimcarb, TDE, tebufenozide,
tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos,
TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos,
tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid,
thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam
oxalate, thiodicarb, thiofanox, thiometon, thiosultap,
thiosultap-disodium, thiosultap-monosodium, thuringiensin,
tolfenpyrad, tralomethrin, transfluthrin, transpermethrin,
triarathene, triazamate, triazophos, trichlorfon,
trichlormetaphos-3, trichloronat, trifenofos, triflumuron,
trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb,
zeta-cypermethrin, zolaprofos, and any combinations thereof.
[0066] Additionally, the compounds described herein may be combined
with herbicides that are compatible with the compounds of the
present disclosure in the medium selected for application, and not
antagonistic to the activity of the present compounds to form
pesticidal mixtures and synergistic mixtures thereof. The
fungicidal compounds of the present disclosure may be applied in
conjunction with one or more herbicides to control a wide variety
of undesirable plants. When used in conjunction with herbicides,
the presently claimed compounds may be formulated with the
herbicide(s), tank-mixed with the herbicide(s) or applied
sequentially with the herbicide(s). Typical herbicides include, but
are not limited to: 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB;
3,4-DB; 2,4-DEB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB;
acetochlor, acifluorfen, aclonifen, acrolein, alachlor,
allidochlor, alloxydim, allyl alcohol, alorac, ametridione,
ametryn, amibuzin, amicarbazone, amidosulfuron, amino
cyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole, ammonium
sulfamate, anilofos, anisuron, asulam, atraton, atrazine,
azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid,
benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron,
bensulide, bentazone, benzadox, benzfendizone, benzipram,
benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron,
bicyclopyrone, bifenox, bilanafos, bispyribac, borax, bromacil,
bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon,
butachlor, butafenacil, butamifos, butenachlor, buthidazole,
buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid,
cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor,
carbasulam, carbetamide, carboxazole chlorprocarb, carfentrazone,
CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop,
chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac,
chlorfenprop, chlorflurazole, chlorflurenol, chloridazon,
chlorimuron, chlornitrofen, chloropon, chlorotoluron, chloroxuron,
chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid,
cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim,
cliodinate, clodinafop, clofop, clomazone, clomeprop, cloprop,
cloproxydim, clopyralid, cloransulam, CMA, copper sulfate, CPMF,
CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate,
cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyperquat,
cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet,
delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil,
dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop,
diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron,
difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate,
dimethachlor, dimethametryn, dimethenamid, dimethenamid-P,
dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam,
dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul,
dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endothal,
epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron,
ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxysulfuron,
etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop,
fenoxaprop, fenoxaprop-P, fenoxasulfone, fenteracol, fenthiaprop,
fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M,
flazasulfuron, florasulam, fluazifop, fluazifop-P, fluazolate,
flucarbazone, flucetosulfuron, fluchloralin, flufenacet,
flufenican, flufenpyr, flumetsulam, flumezin, flumiclorac,
flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen,
fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil,
flupropanate, flupyrsulfuron, fluridone, flurochloridone,
fluroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron,
fosamine, furyloxyfen, glufosinate, glufosinate-P, glyphosate,
halosafen, halosulfuron, haloxydine, haloxyfop, haloxyfop-P,
hexachloroacetone, hexaflurate, hexazinone, imazamethabenz,
imazamox, imazapic, imazapyr, imazaquin, imazethapyr,
imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane,
iodosulfuron, ioxynil, ipazine, ipfencarbazone, iprymidam,
isocarbamid, isocil, isomethiozin, isonoruron, isopolinate,
isopropalin, isoproturon, isouron, isoxaben, isoxachlortole,
isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen,
lenacil, linuron, MAA, MAMA, MCPA, MCPA-thioethyl, MCPB, mecoprop,
mecoprop-P, medinoterb, mefenacet, mefluidide, mesoprazine,
mesosulfuron, mesotrione, metam, metamifop, metamitron,
metazachlor, metazosulfuron, metflurazon, methabenzthiazuron,
methalpropalin, methazole, methiobencarb, methiozolin, methiuron,
methometon, methoprotryne, methyl bromide, methyl isothiocyanate,
methyldymron, metobenzuron, metobromuron, metolachlor, metosulam,
metoxuron, metribuzin, metsulfuron, molinate, monalide, monisouron,
monochloroacetic acid, monolinuron, monuron, morfamquat, MSMA,
naproanilide, napropamide, naptalam, neburon, nicosulfuron,
nipyraclofen, nitralin, nitrofen, nitrofluorfen, norflurazon,
noruron, OCH, orbencarb, ortho-dichlorobenzene, orthosulfamuron,
oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxasulfuron,
oxaziclomefone, oxyfluorfen, parafluron, paraquat, pebulate,
pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol,
pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham,
phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury
acetate, picloram, picolinafen, pinoxaden, piperophos, potassium
arsenite, potassium azide, potassium cyanate, pretilachlor,
primisulfuron, procyazine, prodiamine, profluazol, profluralin,
profoxydim, proglinazine, prometon, prometryn, propachlor,
propanil, propaquizafop, propazine, propham, propisochlor,
propoxycarbazone, propyrisulfuron, propyzamide, prosulfalin,
prosulfocarb, prosulfuron, proxan, prynachlor, pydanon, pyraclonil,
pyraflufen, pyrasulfotole, pyrazolynate, pyrazosulfuron,
pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol,
pyridate, pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac,
pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine,
quinonamid, quizalofop, quizalofop-P, rhodethanil, rimsulfuron,
saflufenacil, S-metolachlor, sebuthylazine, secbumeton, sethoxydim,
siduron, simazine, simeton, simetryn, SMA, sodium arsenite, sodium
azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone,
sulfometuron, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA,
tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim,
terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine,
terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr,
thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron,
thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim,
triafamone, tri-allate, triasulfuron, triaziflam, tribenuron,
tricamba, triclopyr, tridiphane, trietazine, trifloxysulfuron,
trifluralin, triflusulfuron, trifop, trifopsime,
trihydroxytriazine, trimeturon, tripropindan, tritac,
tritosulfuron, vernolate, and xylachlor.
[0067] Another embodiment of the present disclosure is a method for
the control or prevention of fungal attack. This method comprises
applying to the soil, plant, roots, foliage, or locus of the
fungus, or to a locus in which the infestation is to be prevented
(for example applying to cereal or grape plants), a fungicidally
effective amount of one or more of the compounds of Formula I. The
compounds are suitable for treatment of various plants at
fungicidal levels, while exhibiting low phytotoxicity. The
compounds may be useful both in a protectant and/or an eradicant
fashion.
[0068] The compounds have been found to have significant fungicidal
effect particularly for agricultural use. Many of the compounds are
particularly effective for use with agricultural crops and
horticultural plants.
[0069] It will be understood by those in the art that the efficacy
of the compound for the foregoing fungi establishes the general
utility of the compounds as fungicides.
[0070] The compounds have broad ranges of activity against
fungicidal pathogens. Exemplary pathogens may include, but are not
limited to, wheat leaf blotch (Septoria tritici, also known as
Mycosphaerella graminicola), brown rust (Puccinia triticina),
stripe rust (Puccinia striiformis), and black sigatoka
(Mycosphaerella fujiensis). The exact amount of the active material
to be applied is dependent not only on the specific active material
being applied, but also on the particular action desired, the
fungal species to be controlled, and the stage of growth thereof,
as well as the part of the plant or other product to be contacted
with the compound. Thus, all the compounds, and formulations
containing the same, may not be equally effective at similar
concentrations or against the same fungal species.
[0071] The compounds are effective in use with plants in a
disease-inhibiting and phytologically acceptable amount. The term
"disease-inhibiting and phytologically acceptable amount" refers to
an amount of a compound that kills or inhibits the plant disease
for which control is desired, but is not significantly toxic to the
plant. This amount will generally be from about 0.1 to about 1000
ppm (parts per million), with 1 to 500 ppm being preferred. The
exact concentration of compound required varies with the fungal
disease to be controlled, the type of formulation employed, the
method of application, the particular plant species, climate
conditions, and the like. A suitable application rate is typically
in the range from about 0.10 to about 4 pounds/acre (about 0.01 to
0.45 grams per square meter, g/m.sup.2).
[0072] Any range or desired value given herein may be extended or
altered without losing the effects sought, as is apparent to the
skilled person for an understanding of the teachings herein.
[0073] The compounds of Formula I may be made using well-known
chemical procedures. Intermediates not specifically mentioned in
this disclosure are either commercially available, may be made by
routes disclosed in the chemical literature, or may be readily
synthesized from commercial starting materials utilizing standard
procedures.
General Schemes
[0074] The following schemes illustrate approaches to generating
picolinamide compounds of Formula (I). The following descriptions
and examples are provided for illustrative purposes and should not
be construed as limiting in terms of substituents or substitution
patterns.
[0075] As shown in Scheme 1, step a, a compound of Formula III can
be prepared via protection of Formula II with a protecting group,
for example, tert-butoxycarbonyl (Boc) to give a
tert-butylcarbamate, followed by cleavage of the picolinate head
under alkaline conditions, such as those achieved with
N,N-diethylethylenediamine. Compounds of Formula IVa can then be
prepared under oxidative conditions, for example, with sodium
periodate (NaIO.sub.4) and ruthenium trichloride (RuCl.sub.3) in a
solvent system such as acetonitrile (CH.sub.3CN), ethyl acetate
(EtOAc) and water (H.sub.2O). Compounds of Formula V, where X is
halogen, for example, iodo and bromo, can be prepared from
compounds of Formula IVa by treatment with
2-mercaptopyridine-N-oxide, and irradiation or heating of the
resultant ester in the presence of a halogen source, for example
iodoform and bromotrichloromethane, to provide compounds of Formula
V, as in step c. Compounds of Formula VIa where R.sub.2 is H can be
prepared by reduction of V, wherein X is bromo, under radical
conditions with a hydride such as tributyltin hydride (Bu.sub.3SnH)
and an initiator such as azobisisobutyronitrile (AIBN) as in step
d. Compounds of Formula VIa where R.sub.2 is substituted phenyl can
be prepared as in step e by treating compounds of Formula V,
wherein X is halo, with a substituted arylhalide in the presence of
zinc dust, a catalyst such as, for example
tris(dibenzylideneacetone)dipalladium (Pd.sub.2(dba).sub.3), and a
ligand such as tri(ortho-tolyl)phosphine (P(o-tolyl).sub.3) in a
solvent such as N,N-dimethylformamide (DMF).
##STR00003## ##STR00004##
[0076] In Scheme 2, compounds of Formula Ib, where R.sub.2 is as
previously defined, can be prepared through removal of the amine
protecting group under appropriate conditions. For example, a Boc
group can be removed via treatment with a strong acid, such as a
solution of hydrogen chloride (HCl) in dioxane or trifluoroacetic
acid (TFA) in a solvent such as dichloromethane (DCM,
CH.sub.2Cl.sub.2). Subsequent formation of the amide bond is
achieved via treatment with a picolinic acid, such as
3-hydroxy-4-methoxy-picolinic acid, in the presence of a peptide
coupling reagent, such as
(dimethylamino)-N,N-dimethyl(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)met-
haniminium hexafluorophosphate (HATU) in a solvent such as
CH.sub.2Cl.sub.2.
##STR00005##
[0077] In Scheme 3, compounds of Formula Ic, where R.sub.2 is as
previously defined can be prepared from compounds of Formula Ib by
reaction with the appropriate alkyl halide in the presence of a
reagent such as sodium iodide (NaI) and a base such as sodium
carbonate (Na.sub.2CO.sub.3) in a solvent such as acetone or an
acyl halide in the presence of an amine base, such as pyridine or
triethylamine, in an aprotic solvent such as DCM.
##STR00006##
[0078] In Scheme 4, compound VII can be made as in step a from
compound VIc by reaction with a reducing agent such as borane
(BH.sub.3) in a polar, aprotic solvent such as tetrahydrofuran
(THF). Compounds of Formula VIII, wherein R.sub.4 is as previously
defined, can be prepared from compound VII, as shown in step b, by
reaction with R.sub.4C(O)X wherein X is a halogen, in the presence
of a base, such as pyridine, and in a solvent such as
CH.sub.2Cl.sub.2. Compounds of Formula IXa, where R.sub.4 is alkyl,
phenyl, or substituted phenyl can be prepared from compound VII, as
shown in step c, by reaction with a substituted sulfonyl halide in
the presence of an organic base, such as pyridine, in a solvent
such as CH.sub.2Cl.sub.2. Compound X can be prepared from compound
VII as shown in step cd Subjection of VII to oxidative conditions,
for example, treatment with Dess-Martin periodinane affords the
aldehyde, which is then treated with a fluorinating agent such as
Deoxo-Fluor.TM. in an aprotic solvent system such as toluene and
CH.sub.2Cl.sub.2 to give difluoro-substituted compound X. Compounds
of Formula XI, wherein R.sub.4 is arylalkyl, can be synthesized
from compound VII by reaction with an aryl-alkylating agent, such
as 2-benzyloxy-1-methylpyridinium triflate, in the presence of a
reagent such as magnesium oxide (MgO) in a solvent such as
.alpha.,.alpha.,.alpha.-trifluorotoluene, as in step e. Compounds
of Formula XII, wherein R.sub.4 is alkyl, can be prepared from
compound VII, as shown in step f, by alkylating with a reagent such
as trimethyloxonium tetrafluoroborate in the presence of a drying
reagent such as sodium sulfate (Na.sub.2SO.sub.4) and a base, such
as, for example, N,N,N',N'-tetramethylnaphthalene-1,8-diamine
(Proton Sponge.TM.) in an anhydrous, aprotic solvent such as
CH.sub.2Cl.sub.2. Compounds of Formula XIII, wherein R.sub.4 is as
previously defined, can be synthesized from compounds of Formula
VIc, as shown in step g, by treatment with an alcohol such as
tert-butanol (t-BuOH), in the presence of a a coupling reagent such
as N,N'-methanediylidenedipropan-2-amine
(N,N-diisopropylcarbodiimide, DIC) in the presence of a base such
as 4-dimethylaminopyridine (DMAP) in a solvent such as
CH.sub.2Cl.sub.2.
##STR00007##
[0079] Compounds of Formula XIV, wherein R.sub.5 is as previously
defined, can be prepared as shown in Scheme 5, step a. Treating
compounds of Formula IXb, wherein R.sub.4 is as previously defined,
with a nucleophile such as sodium azide (NaN.sub.3) in a solvent
such as DMF affords an intermediate azide that can be reacted with
an alkyne such as 1-chloro-3-ethynylbenzene in the presence of a
copper salt, such as copper sulfate (CuSO.sub.4) and sodium
ascorbate in a solvent system such as DMF and H.sub.2O to give
compounds of Formula XIV. Compound XV can be prepared from
compounds of Formula IXb, as shown in step b, by reaction with NaI
in a solvent such as DMF. Compounds of Formula XVI, wherein R.sub.4
is aryl, can be prepared from compound XV, as illustrated in step
c, by reaction with zinc (Zn) in the presence of iodine (I.sub.2)
to form an intermediate organozinc species. Reaction of the
organozinc intermediate with an aryl halide in the presence of a
palladium catalyst such as
dichlorobis[tris(o-tolyl)phospine]palladium(II)
(PdCl.sub.2[P(o-Tol).sub.3].sub.2) in a solvent such as DMF affords
compounds of Formula XVI. Compound XVII can be prepared, as
depicted in step d, from compound XV by reaction with a hydride
source such as Bu.sub.3SnH, in the presence of an initiator such as
AIBN and an aromatic solvent such as benzene. Compound XVIII can be
prepared from compounds of Formula IXb by treatment with NaI in DMF
at an elevated temperature for 48 hours (h), as shown in step
e.
##STR00008##
[0080] In Scheme 6, compounds of Formula XIX can be prepared from
compounds of Formula IIIb by treating with hydrogen gas (H.sub.2)
under high pressures, such as 500 pounds per square inch (psi), at
elevated temperatures, such as 60.degree. C., and in the presence
of a catalyst such as 5% rhodium on carbon (Rh/C).
##STR00009##
[0081] The following examples are presented to illustrate the
various aspects of the compounds of the present disclosure and
should not be construed as limitations to the claims.
EXAMPLES
Example 1
Step 1: Preparation of
(3S,6S,7R,8R)-8-benzyl-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-1,-
5-dioxonan-7-yl isobutyrate
##STR00010##
[0083] To a suspension of
(3S,6S,7R,8R)-8-benzyl-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate (UK-2A; 10.0 grams (g), 19.4
millimole (mmol)) and DMAP (237 milligrams (mg), 1.9 mmol) in
CH.sub.3CN (49 milliliters (mL)) was added di-tert-butyl
dicarbonate (8.70 g, 39.8 mmol), and the mixture was stirred for 30
minutes (min). To the resulting clear solution was slowly added
N,N-diethylethylenediamine and stirring was continued at room
temperature (about 22.degree. C.) for 90 min. The CH.sub.3CN was
removed in vacuo and the resulting residue was dissolved in ethyl
ether (Et.sub.2O; 200 mL) and washed with 1N (Normal) aqueous (aq)
HCl (100 mL). The phases were separated and the aqueous phase was
extracted further with Et.sub.2O (25 mL). The organic extracts were
combined, washed successively with 0.5N aq HCl and saturated
(sat'd) aq sodium bicarbonate (NaHCO.sub.3), dried over magnesium
sulfate (MgSO.sub.4), filtered, and concentrated to give a white
glassy solid. Purification of the crude extract by column
chromatography (Silica gel (SiO.sub.2); 0.fwdarw.3%
EtOAc/CH.sub.2Cl.sub.2) gave the title compound (2.41 g, 27%) as a
white solid: mp 143-145.degree. C.; IR (neat) 1768, 1740, 1693,
1515 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.27-7.10
(m, 5H), 5.19 (m, 2H), 5.18 (dd, J=11.9, 7.6 Hz, 1H), 4.91 (td,
J=12.2, 6.0 Hz, 1H), 4.79 (s, 1H), 3.43 (s, 1H), 3.00-2.86 (m, 2H),
2.68-2.58 (m, 2H), 1.43 (s, 9H), 1.30 (d, J=6.3 Hz, 3H), 1.23 (d,
J=7.0, Hz, 3H), 1.23 (d, J=7.0, Hz, 3H); .sup.13C NMR (400 MHz,
CDCl.sub.3): 175.6, 171.7, 170.8, 154.7, 137.9, 128.7, 128.5,
126.6, 80.5, 75.0, 74.4, 65.9, 51.9, 51.4, 34.5, 34.1, 28.2, 18.9,
17.8; ESIMS m/z 462.5 ([M-H].sup.-).
Example 1
Step 2: Preparation of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl)acetic acid
##STR00011##
[0085] To a solution of
(3S,6S,7R,8R)-8-benzyl-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-1,-
5-dioxonan-7-yl isobutyrate (10 g, 21.6 mmol) in CH.sub.3CN (72
mL), EtOAc (72 mL), and H.sub.2O (575 mL) were added NaIO.sub.4
(134 g, 626 mmol) and RuCl.sub.3-trihydrate (282 mg, 1.08 mmol).
The reaction was stirred at room temperature (about 22.degree. C.)
overnight. The resulting white suspension was diluted with water
(700 mL) and extracted with CH.sub.2Cl.sub.2 (5.times.), and EtOAc
(2.times.). Activated carbon (12 g) was added to the combined
organic extracts (.about.2 L) and the mixture was stirred
vigorously for 1 h. The mixture was filtered through Celite.RTM.,
and the filtrate was dried over MgSO.sub.4, filtered, and
concentrated to give the title compound (7.71 g, 83%) as a gray
solid: mp 164-167.degree. C.; IR (neat) 3375, 3293 (br), 1773,
1743, 1731, 1686, 1157 cm.sup.-1; .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 5.30 (m, 2H), 5.04 (t, J=9.7 Hz, 1H), 4.90 (m, 2H), 3.65
(s, 1H), 2.97 (m, 2H), 2.62 (m, 1H), 2.41 (m, 1H), 1.45 (s, 9H),
1.29 (d, J=6.2 Hz, 3H), 1.22 (d, J=7.0 Hz, 6H); .sup.13C NMR (101
MHz, CDCl.sub.3) .delta. 175.78, 175.61, 171.53, 171.03, 154.88,
80.85, 74.44, 74.05, 65.56, 51.16, 45.40, 34.03, 33.44, 28.24,
18.94, 18.83, 17.77; ESIMS m/z 430.4 ([M-H].sup.-).
Example 1
Step 3: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(iodomethyl)-6-methyl-4,9-di-
oxo-1,5-dioxonan-7-yl isobutyrate
##STR00012##
[0087] To a solution of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl)acetic acid (9.90 g, 23 mmol) in THF
(100 mL) was added N-methylmorpholine (2.5 mL, 23 mmol) followed by
isobutylchloroformate (3.0 mL, 23 mmol) at 0.degree. C. After
stirring for 10 min, a solution of 2-mercaptopyridine N-oxide (3.5
g, 27.5 mmol) and triethylamine (TEA; 3.8 mL, 27.5 mmol) in THF (50
mL) was added slowly and the reaction stirred at 0.degree. C. for
1.5 h in the dark (wrapped flask in aluminum foil). The
precipitated N-methylmorpholine-HCl salt was removed by vacuum
filtration and the filtrate was removed in vacuo at ambient
temperature (about 22.degree. C.). The oily residue was dissolved
in CH.sub.2Cl.sub.2 (250 mL) and treated with Iodoform (11.8 g, 30
mmol). The solution was transferred to a UV reactor and irradiated
with a 450 W mercury lamp with water cooling. After 1 h, the orange
solution was removed from the reactor, adsorbed to Celite.RTM. and
partially purified via flash chromatography (SiO.sub.2, 20%
EtOAc/DCM). Additional flash chromatography (SiO.sub.2, 10%
EtOAc/DCM) followed by recrystallization from EtOAc/hexanes
afforded the title compound (5.99 g, 51%) as an off-white solid: mp
168-171.degree. C.; IR (neat) 3386, 2977, 1771, 1760, 1742, 1689,
1510 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 5.36 (s,
1H), 5.21 (m, 1H), 5.00 (t, J=9.7 Hz, 1H), 4.86 (m, 2H), 3.68 (brs,
1H), 3.31 (dd, J=11.5, 9.3 Hz, 1H), 3.02 (m, 2H), 2.63 (m, 1H),
1.45 (s, 9H), 1.27 (d, J=6.3 Hz, 3H), 1.22 (d, J=7.0 Hz, 6H); ESIMS
m/z 536.3 ([M+Na].sup.+).
Example 1
Step 4: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(4-fluorobenzyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00013##
[0089] To a suspension of freshly ground zinc dust (139 mg, 2.13
mmol) in an oven-dried flask containing a stir bar were added DMF
(200 .mu.L; just covered the dust) and iodine (54 mg, 0.21 mmol),
and the mixture was stirred for 1 min. To the mixture was added a
solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(iodomethyl)-6-methyl-4,9-di-
oxo-1,5-dioxonan-7-yl isobutyrate (273 mg, 0.53 mmol) in DMF (1 mL)
slowly at 40.degree. C. After 15 min, the reaction mixture was
cooled to ambient temperature (about 22.degree. C.) and a solution
of Pd.sub.2(dba).sub.3 (12 mg, 0.01 mmol), (o-tol).sub.3P (16 mg,
0.05 mmol), and 1-fluoro-4-iodobenzene (80 .mu.L, 0.69 mmol) in DMF
(900 .mu.L) was added to the reaction and the reaction was warmed
back to 40.degree. C. and stirring continued for 1.5 hr. The
mixture was cooled, diluted with EtOAc (2 mL), and filtered through
a 0.45 micrometer (.mu.m) fritted filter disc. The solution was
diluted with EtOAc (100 mL), washed with H.sub.2O (3.times.), dried
over MgSO.sub.4, filtered, and concentrated. Purification by column
chromatography (SiO.sub.2, 020% EtOAc/hexanes) gave the title
compound (96 mg, 38%) as a white, glassy solid: mp 58-66.degree.
C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.08 (m, 2H), 6.95
(m, 2H), 5.22-5.14 (m, 3H), 4.93 (m, 1H), 4.80 (m, 1H), 3.46 (m,
1H), 3.00-2.80 (m, 2H), 2.64 (m, 2H), 1.44 (s, 9H), 1.31 (d, J=6.4
Hz, 3H), 1.25 (d, J=7.0 Hz, 3H), 1.25 (d, J=7.0 Hz, 3H); ESIMS m/z
503.3 ([M+Na].sup.+).
Example 1
Step 5: Preparation of
(3S,6S,7R,8R)-8-(4-fluorobenzyl)-3-(3-hydroxy-4-methoxypicolinamido)-6-me-
thyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 1)
##STR00014##
[0091] Method A:
[0092] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(4-fluorobenzyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate (90 mg, 0.19 mmol) in
CH.sub.2Cl.sub.2 (2 mL) was added TFA (1 mL) and the reaction was
stirred for 1.5 hr and then concentrated. The residue was dissolved
in CH.sub.2Cl.sub.2 (75 mL) and the solution was washed with sat'd
aqueous NaHCO.sub.3, dried over MgSO.sub.4, filtered, and
concentrated to dryness. The residue was dissolved in
CH.sub.2Cl.sub.2 (1.8 mL), and the solution was sequentially
treated with 3-hydroxy-4-methoxypicolinic acid (41 mg, 0.24 mmol),
N-methylmorpholine (123 .mu.L, 1.12 mmol), HATU (107 mg, 0.28 mmol)
and a catalytic amount of DMAP. The reaction was stirred at ambient
temperature (about 22.degree. C.) for 3 h and then loaded directly
onto a 12 g SiO.sub.2 column for purification by flash
chromatography (0.fwdarw.20% EtOAc/CH.sub.2Cl.sub.2 followed by 80%
EtOAc/CH.sub.2Cl.sub.2) to give the title compound (66 mg, 66%) as
a white solid.
[0093] Method B:
[0094]
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(4-fluorobenzyl)-6-met-
hyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (83 mg, 0.17 mmol) was
treated with 4N HCl in dioxane (2 mL), and the reaction was stirred
at ambient temperature (about 22.degree. C.) overnight. The
reaction was concentrated in vacuo, and the residue was dissolved
in CH.sub.2Cl.sub.2 (1.8 mL). To this solution were added
3-hydroxy-4-methoxypicolinic acid (38 mg, 0.22 mmol),
N-methylmorpholine (114 .mu.L, 1.03 mmol), HATU (98 mg, 0.26 mmol)
and a catalytic amount of DMAP sequentially. The reaction was
stirred at ambient temperature for about 3 h and the resulting
clear solution was loaded directly onto a SiO.sub.2 column for
purification by flash chromatography (0.fwdarw.20%
EtOAc/CH.sub.2Cl.sub.2 followed by 80% EtOAc/CH.sub.2Cl.sub.2) to
give the title compound (18 mg, 20%) as a white solid: mp
208-210.degree. C.; IR (neat)=3359, 1746, 1652, 1531 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.77 (s, 1H), 8.59 (d,
J=8.2 Hz, 1H), 7.99 (d, J=5.2 Hz, 1H), 7.11-7.07 (m, 2H), 6.95 (t,
J=8.7 Hz, 2H), 6.88 (d, J=5.2 Hz, 1H), 5.32 (dd, J=33.3, 24.1 Hz,
2H), 5.20-5.09 (m, 2H), 4.97 (m, 1H), 3.94 (s, 3H), 3.62 (brs, 1H),
3.09-2.80 (m, 2H), 2.80-2.54 (m, 2H), 1.32 (d, J=6.3 Hz, 3H), 1.25
(d, J=7.0 Hz, 3H), 1.24 (d, J=7.0 Hz, 3H); .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 175.61, 171.63, 169.72, 168.98, 162.94, 160.50,
155.44, 148.84, 140.74, 133.47, 130.35, 130.27, 129.92, 115.58,
115.37, 109.73, 74.94, 74.72, 65.28, 56.14, 52.15, 49.94, 34.13,
33.78, 18.99, 17.85; ESIMS m/z 532.9 ([M+H].sup.+).
[0095] Compounds 2-10, 11 (Step 4 omitted), and 12-18 were made as
described in Example 1.
Example 2
Preparation of
2-((3S,7R,8R,9S)-8-(isobutyryloxy)-3-(3-(isobutyryloxymethoxy)-4-methoxyp-
icolinamido)-9-methyl-2,6-dioxo-1,5-dioxonan-7-yl)ethyl benzoate
(Compound 19)
##STR00015##
[0097] To a mixture of
2-((3S,7R,8R,9S)-3-(3-hydroxy-4-methoxypicolinamido)-8-(isobutyryloxy)-9--
methyl-2,6-dioxo-1,5-dioxonan-7-yl)ethyl benzoate (50 mg, 0.087
mmol), Na.sub.2CO.sub.3 (15 mg, 0.14 mmol) and NaI (3.09 mg, 0.021
mmol) in acetone (0.6 mL) was added chloromethyl isobutyrate (15.4
mg, 0.114 mmol) slowly at room temperature (about 22.degree. C.).
The resulting reaction mixture was warmed to 50.degree. C. and
stirred at 50.degree. C. overnight. The solvent was evaporated and
the crude residue was purified via flash chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (35 mg, 76%)
as an off-white solid: mp 48-50.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.55 (d, J=7.9 Hz, 1H), 8.26 (d, J=5.5 Hz, 1H),
8.04-7.87 (m, 2H), 7.55 (t, J=7.4 Hz, 1H), 7.43 (t, J=7.5 Hz, 2H),
6.95 (d, J=5.4 Hz, 1H), 5.85-5.62 (m, 2H), 5.41 (s, 1H), 5.26-5.06
(m, 2H), 4.94 (dd, J=9.8, 6.3 Hz, 1H), 4.42-4.19 (m, 2H), 3.92 (d,
J=14.3 Hz, 3H), 3.65 (s, 1H), 2.76 (t, J=9.5 Hz, 1H), 2.62 (dt,
J=10.8, 5.5 Hz, 1H), 2.58-2.47 (m, 1H), 2.30 (s, 1H), 1.82 (s, 1H),
1.29 (d, J=6.3 Hz, 3H), 1.21 (dd, J=7.0, 0.9 Hz, 6H), 1.13 (d,
J=7.0 Hz, 6H); ESIMS m/z 673 ([M+H]
[0098] Compounds 20-34 were made as described in Example 2.
Example 3
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-hydroxyethyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00016##
[0100] To a solution of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl)acetic acid (2.0 g, 4.64 mmol) in THF
(15 mL) was added borane (1.0 M in THF, 5.56 mL, 5.56 mmol) at
0.degree. C. After 15 min the ice bath was removed and the reaction
was allowed to warm to room temperature (about 22.degree. C.).
After an additional 1.5 h, the reaction was quenched with EtOAc (10
mL) and washed successively with 0.5 N HCl (10 mL) and sat'd
aqueous NaHCO.sub.3 (10 mL). The phases were separated and the
organic phase was dried over MgSO.sub.4, filtered, and concentrated
in vacuo to give the title compound (1.38 g, 72%) as a white solid:
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 5.40-5.19 (m, 2H), 5.07
(t, J=9.9 Hz, 1H), 4.95-4.75 (m, 2H), 3.74-3.52 (m, 3H), 2.83-2.68
(m, 1H), 2.61 (dt, J=13.9, 7.0 Hz, 1H), 2.07-1.90 (m, 1H),
1.70-1.52 (m, 1H), 1.44 (s, 9H), 1.27 (d, J=6.3 Hz, 3H), 1.20 (d,
J=7.0 Hz, 6H); ESIMS m/z 440.3 ([M+Na].sup.+).
Example 3
Step 2: Preparation of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl)ethyl benzoate
##STR00017##
[0102] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-hydroxyethyl)-6
methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (200 mg, 0.479 mmol)
in pyridine (0.5 mL) and CH.sub.2Cl.sub.2 (1 mL) was added benzoyl
chloride (195 mg, 0.958 mmol) at room temperature (about 22.degree.
C.), and the reaction mixture was stirred at room temperature for
12 h. The solvents were removed under vacuum and the residue was
purified by column chromatography (SiO.sub.2, hexanes/EtOAc
gradient) to give the title compound (268 mg, 74%) as a white
solid: .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.97 (dd, J=8.5,
1.0 Hz, 2H), 7.56-7.40 (m, J=10.6, 3H), 5.39-5.15 (m, 2H), 5.10 (t,
J=9.9 Hz, 1H), 4.97-4.73 (m, 2H), 4.42-4.29 (m, 1H), 4.25 (m, 1H),
3.57-3.35 (m, 1H), 2.73 (t, J=9.5 Hz, 1H), 2.62 (dt, J=14.0, 7.0
Hz, 1H), 2.36-2.18 (m, 1H), 1.90-1.71 (m, 1H), 1.46 (s, 9H), 1.28
(d, J=6.4 Hz, 3H), 1.21 (dd, J=7.0, 1.0 Hz, 6H); ESIMS m/z 544
([M+Na].sup.+).
Example 3
Step 3: Preparation of
2-((3S,7R,8R,9S)-3-(3-hydroxy-4-methoxypicolinamido)-8-(isobutyryloxy)-9--
methyl-2,6-dioxo-1,5-dioxonan-7-yl)ethyl benzoate (Compound 35)
##STR00018##
[0104] Compound 35 was prepared in the same manner as described in
Example 1, Step 5, Method A to give the title compound (140 mg,
48%) as a white solid: mp 172-174.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.78 (d, J=0.5 Hz, 1H), 8.61 (d, J=8.2 Hz,
1H), 8.07-7.87 (m, 3H), 7.65-7.53 (m, 1H), 7.50-7.39 (m, 2H), 6.88
(d, J=5.1 Hz, 1H), 5.40 (s, 1H), 5.27-5.08 (m, 2H), 4.96 (dq,
J=12.5, 6.3 Hz, 1H), 4.42-4.20 (m, 2H), 3.95 (s, 3H), 3.64 (s, 1H),
2.86-2.72 (m, 1H), 2.63 (dt, J=14.0, 7.0 Hz, 1H), 2.37-2.22 (m,
1H), 1.81 (s, 1H), 1.31 (d, J=6.3 Hz, 3H), 1.22 (dd, J=7.0, 1.2 Hz,
6H); ESIMS m/z 573 ([M+H]
[0105] Compounds 36-43 were made as described in Example 3.
Example 4
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-methoxyethyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00019##
[0107] A round bottom flask was charged with
(3S,6S,7R,8R)-3-(tert-butoxycarbonyl-amino)-8-(2-hydroxyethyl)-6-methyl-4-
,9-dioxo-1,5-dioxonan-7-yl isobutyrate (200 mg, 0.48 mmol), Proton
Sponge.TM. (700 mg, 4.05 mmol), Na.sub.2SO.sub.4 in
CH.sub.2Cl.sub.2 (10 mL) at 0.degree. C. To the resulting
suspension was added trimethyloxonium tetrafluoroborate
(Me.sub.3OBF.sub.4, 320 mg, 2.16 mmol), and the suspension was
warmed to room temperature (about 22.degree. C.) and stirred for 5
h. The mixture was diluted with EtOAc, filtered, and the filtrate
was washed successively with water and 1M NaHSO.sub.4. The organics
were dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated under reduced pressure. Purification of the crude
product via column chromatography (hexanes/EtOAc gradient) afforded
the title compound (140 mg, 71%) as a clear oil: .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 5.41-5.16 (m, J=0.9 Hz, 2H), 5.06 (t,
J=9.9 Hz, 1H), 4.94-4.73 (m, 2H), 3.69-3.52 (m, 1H), 3.42-3.27 (m,
2H), 3.26 (s, J=0.9 Hz, 3H), 2.80-2.67 (m, 1H), 2.60 (dt, J=13.9,
7.0 Hz, 1H), 2.08-1.86 (m, 1H), 1.66-1.55 (m, 1H), 1.45 (s, 9H),
1.27 (d, J=6.3 Hz, 3H), 1.20 (d, J=7.0 Hz, 6H); ESIMS m/z 454
([M+Na]
Example 4
Step 2: Preparation of
(3S,6S,7R,8R)-3-(3-hydroxy-4-methoxypicolinamido)-8-(2-methoxyethyl)-6-me-
thyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 44)
##STR00020##
[0109] Compound 44 was prepared in the same manner as described in
Example 1, Step 5, Method A to give the title compound (78 mg, 48%)
as a white solid: mp 128-130.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.81 (s, 1H), 8.67 (d, J=8.3 Hz, 1H), 8.01
(dd, J=5.2, 0.5 Hz, 2H), 6.90 (d, J=5.2 Hz, 2H), 5.62-5.37 (m, 1H),
5.30-5.16 (m, J=14.9, 8.1 Hz, 2H), 5.09 (q, J=9.5 Hz, 2H),
5.02-4.89 (m, 2H), 3.95 (s, 3H), 3.81 (s, 1H), 3.45-3.29 (m, 2H),
3.27 (s, 2H), 2.85-2.72 (m, 1H), 2.62 (ddd, J=11.8, 8.1, 5.9 Hz,
1H), 2.08-1.92 (m, 2H), 1.84-1.57 (m, 2H), 1.30 (d, J=6.2 Hz, 3H),
1.22 (d, J=7.0 Hz, 6H); ESIMS m/z 439 ([M+H]
[0110] Compound 45 was made as described in Example 4.
Example 5
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6,8-dimethyl-4,9-dioxo-1,5-dio-
xonan-7-yl isobutyrate
##STR00021##
[0112] To a solution of
(3S,6S,7R,8R)-8-(bromomethyl)-3-(tert-butoxycarbonylamino)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate (238 mg, 0.51 mmol) in benzene
(3 mL) was added Bu.sub.3SnH (178 mg, 0.61 mmol) and AIBN (2 mg) at
room temperature (about 22.degree. C.). The reaction solution was
heated to reflux, stirred for 1 hr, and the solution was cooled to
room temperature. The solvent was removed under vacuum and the
residue was purified via column chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (185 mg, 94%)
as a white solid: .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
5.40-5.12 (m, 2H), 5.00 (t, J=9.8 Hz, 1H), 4.93-4.71 (m, 2H),
3.69-3.47 (m, 1H), 2.69-2.50 (m, 2H), 1.45 (s, J=4.7 Hz, 9H), 1.28
(d, J=6.3 Hz, 3H), 1.21 (dd, J=7.0, 1.2 Hz, 6H), 1.13 (d, J=6.7 Hz,
3H); ESIMS m/z 410 ([M+Na].sup.+).
Example 5
Step 2: Preparation of
(3S,6S,7R,8R)-3-(3-hydroxy-4-methoxypicolinamido)-6,8-dimethyl-4,9-dioxo--
1,5-dioxonan-7-yl isobutyrate (Compound 46)
##STR00022##
[0114] Compound 46 was prepared in the same manner as described in
Example 1, Step 5, Method A to give the title compound (74 mg, 37%)
as a white solid: mp 198-200.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.80 (s, 1H), 8.65 (d, J=7.9 Hz, 1H), 8.01 (d,
J=5.2 Hz, 1H), 6.89 (d, J=5.2 Hz, 1H), 5.54-5.31 (m, 1H), 5.19 (dd,
J=15.3, 8.1 Hz, 1H), 5.04 (t, J=9.7 Hz, 1H), 4.94 (td, J=12.2, 6.1
Hz, 1H), 3.95 (s, 3H), 3.78 (s, 1H), 2.65 (ddt, J=20.9, 13.8, 6.8
Hz, 2H), 1.30 (d, J=6.1 Hz, 3H), 1.22 (d, J=7.0 Hz, 6H), 1.16 (d,
J=6.7 Hz, 3H); ESIMS m/z 439 ([M+H].sup.1).
Example 6
Step 1: Preparation of
(3S,6S,7R,8R)-8-(2-tert-butoxy-2-oxoethyl)-3-(tert-butoxycarbonylamino)-6-
-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00023##
[0116] To a solution of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl) acetic acid (400 mg, 0.928 mmol) in
CH.sub.2Cl.sub.2 (2 mL) was added tert-butyl alcohol (3.44 mg, 4.64
mmol) and DMAP (91 mg, 0.744 mmol) at room temperature (about
22.degree. C.). The solution was cooled to 0.degree. C. and
N,N'-methanediylidenedipropan-2-amine (172 uL, 1.11 mmol) was
added. The reaction mixture was warmed to room temperature, stirred
for 2 h, and then loaded directly onto a SiO.sub.2 column and
purified by flash chromatography (hexanes/EtOAc gradient) to give
the title compound (380 mg, 84%) as a white solid: mp
170-172.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
5.44-5.15 (m, 2H), 5.08-4.94 (m, 1H), 4.93-4.75 (m, 2H), 3.74-3.54
(m, 1H), 2.98-2.87 (m, 1H), 2.83-2.71 (m, 1H), 2.61 (hept, J=7.0
Hz, 1H), 2.32-2.21 (m, 1H), 1.44 (s, 9H), 1.40 (s, 9H), 1.27 (d,
J=6.3 Hz, 3H), 1.21 (dd, J=7.0, 1.6 Hz, 6H); ESIMS m/z 410
([M+Na]).
Example 6
Step 2: Preparation of
(3S,6S,7R,8R)-8-(2-tert-butoxy-2-oxoethyl)-3-(3-hydroxy-4-methoxypicolina-
mido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound
47)
##STR00024##
[0118] To a solution of
(3S,6S,7R,8R)-8-(2-tert-butoxy-2-oxoethyl)-3-(tert-butoxycarbonylamino)-6-
-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (130 mg, 0.267
mmol) in EtOAc (3 mL) was added 1M HCl in EtOAc and the solution
was stirred at room temperature (about 22.degree. C.) for 6 h. The
solvent was evaporated and the residue was dissolved in
CH.sub.2Cl.sub.2 (1.5 mL). To this solution was added
3-hydroxy-4-methoxypicolinic acid (58 mg, 0.345 mmol), HATU (139
mg, 0.367 mmol) and N-methylmorpholine (120 mL, 1.09 mmol),
sequentially. The reaction was allowed to stir at ambient
temperature for 12 h and then loaded directly onto a SiO.sub.2
column and purified by flash chromatography (hexanes/EtOAc
gradient) to give the title compound (62 mg, 43%) as a white solid:
mp 192-194.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
11.79 (d, J=0.5 Hz, 1H), 8.63 (d, J=8.3 Hz, 1H), 8.01 (d, J=5.2 Hz,
1H), 6.89 (d, J=5.1 Hz, 1H), 5.45 (s, 1H), 5.21 (dd, J=15.5, 8.3
Hz, 1H), 5.12-5.01 (m, 1H), 5.01-4.87 (m, 1H), 3.95 (s, 3H), 3.80
(d, J=25.0 Hz, 1H), 2.98 (ddd, J=11.8, 9.9, 3.2 Hz, 1H), 2.86-2.74
(m, 1H), 2.62 (dt, J=14.0, 7.0 Hz, 1H), 2.35-2.23 (m, 1H), 1.41 (s,
9H), 1.30 (dd, J=6.2, 2.4 Hz, 3H), 1.22 (dd, J=7.0, 1.6 Hz, 6H);
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 175.50, 172.00, 170.26,
169.90, 169.01, 155.45, 148.86, 140.73, 129.97, 109.74, 81.74,
74.79, 74.07, 65.03, 56.13, 49.80, 45.81, 34.93, 34.02, 27.97,
18.96, 18.84, 17.79; ESIMS m/z 539 ([M+H].sup.+).
[0119] Compounds 48-50 were made as described in Example 6.
Example 7
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-(formyloxy)ethyl)-6-methy-
l-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00025##
[0121] To a solution
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-8-(2
(methylsulfonyloxy)ethyl)-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
(510 mg, 1.03 mmol) in DMF (3 mL) at room temperature (about
22.degree. C.) was added NaI (1 g, 6.7 mmol). The resulting
reaction mixture was heated to 80.degree. C. and stirred for 48 h.
After cooling to room temperature, saturated NaHCO.sub.3 solution
(30 mL) and EtOAc (25 mL) were added. The phases were separated and
the aqueous phase was extracted with EtOAc (2.times.25 mL). The
combined EtOAc extracts were dried over Na.sub.2SO.sub.4, filtered,
and concentrated to dryness. The crude residue was purified via
column chromatography (SiO.sub.2, hexanes/EtOAc gradient) to afford
the title compound (228 mg, 50%) as a white solid (228 mg, 50%): mp
103-104; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.00 (s, 1H),
5.43-5.15 (m, 2H), 5.06 (t, J=9.9 Hz, 1H), 4.93-4.77 (m, 2H), 4.19
(dt, J=11.1, 5.5 Hz, 1H), 4.05 (ddd, J=11.4, 8.9, 4.8 Hz, 1H), 3.60
(s, 1H), 2.71 (td, J=11.4, 2.8 Hz, 1H), 2.67-2.53 (m, 1H),
2.17-2.02 (m, 1H), 1.73 (dt, J=14.7, 7.4 Hz, 1H), 1.45 (s, J=15.6
Hz, 9H), 1.28 (d, J=6.3 Hz, 3H), 1.21 (dd, J=7.0, 0.5 Hz, 6H);
ESIMS m/z 468 ([M+Na].sup.+).
Example 7
Step 2: Preparation of
(3S,6S,7R,8R)-8-(2-(formyloxy)ethyl)-3-(3-hydroxy-4-methoxypicolinamido)--
6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 51)
##STR00026##
[0123] Compound 51 was prepared in the same manner as described in
Example 1, Step 5, Method A to give a white solid (106 mg, 51%): mp
103-105.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 11.78
(s, 1H), 8.64 (d, J=7.9 Hz, 1H), 8.09-7.92 (m, 2H), 6.90 (d, J=5.3
Hz, 1H), 5.47 (s, 1H), 5.21 (d, J=7.0 Hz, 1H), 5.11 (t, J=9.9 Hz,
1H), 5.01-4.88 (m, 1H), 4.21 (dt, J=11.0, 5.4 Hz, 1H), 4.14-4.00
(m, 1H), 3.95 (s, 3H), 3.79 (s, 1H), 2.84-2.69 (m, 1H), 2.63 (dt,
J=14.0, 7.0 Hz, 1H), 2.20-2.06 (m, 1H), 1.78 (s, 1H), 1.31 (d,
J=6.2 Hz, 3H), 1.22 (d, J=7.0 Hz, 6H); ESIMS m/z 498 ([M+H]
Example 8
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-8-(2-oxoeth-
yl)-1,5-dioxonan-7-yl isobutyrate
##STR00027##
[0125] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-hydroxyethyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate (200 mg, 0.48 mmol) in
CH.sub.2Cl.sub.2 at 0.degree. C. was added Dess-Martin reagent (264
mg, 0.62 mmol). The resulting reaction mixture was stirred at
0.degree. C. for 3 h and then at room temperature (about 22.degree.
C.) for another 1 h. The mixture was partitioned between sat'd
aqueous NaHCO.sub.3 solution (20 mL) and EtOAc (25 mL), and the
phases were separated. The aqueous phase was extracted with
additional EtOAc (2.times.25 mL), and the combined EtOAc extracts
were dried over Na.sub.2SO.sub.4, filtered, and the filtrate was
concentrated to dryness. The crude residue was purified via column
chromatography (SiO.sub.2, hexanes/EtOAc gradient) to yield the
intermediate aldehyde (78 mg, 38%) as a colorless oil. A portion of
the oil (50 mg) was dissolved in a mixture of toluene (1 mL) and
CH.sub.2Cl.sub.2 (0.2 mL) and cooled to 0.degree. C. To the
resulting solution was added Deoxo-Fluor.TM. (115 mg, 50% solution
in toluene, 0.26 mg) at 0.degree. C. The reaction solution was
stirred at 0.degree. C. for 2 h and then at room temperature for 1
h. The solvent was removed and the residue was purified via column
chromatography (SiO.sub.2, hexanes/EtOAc gradient) to afford the
title compound (27 mg, 51%) as a white solid: .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 5.80 (tdd, J=56.1, 4.8, 3.1 Hz, 1H), 5.39-5.12
(m, 2H), 5.05 (t, J=9.8 Hz, 1H), 4.89 (ddd, J=12.5, 9.8, 6.3 Hz,
2H), 3.62 (s, 1H), 2.92-2.74 (m, 1H), 2.62 (dt, J=14.0, 7.0 Hz,
1H), 2.50-2.32 (m, 1H), 1.89-1.70 (m, 1H), 1.45 (s, 9H), 1.29 (d,
J=6.2 Hz, 3H), 1.21 (dd, J=7.0, 0.5 Hz, 6H); ESIMS m/z 460
([M+Na].sup.+).
Example 8
Step 2: Preparation of
(3S,6S,7R,8R)-8-(2,2-difluoroethyl)-3-(3-hydroxy-4-methoxypicolinamido)-6-
-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 52)
##STR00028##
[0127] Compound 52 was prepared in the same manner as described in
Example 1, Step 5, Method A to afford the title compound (38 mg,
48%) as a white solid: mp 195-196.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.76 (s, 1H), 8.64 (d, J=8.1 Hz, 1H), 8.01 (d,
J=5.2 Hz, 1H), 6.89 (d, J=5.2 Hz, 1H), 6.06-5.60 (m, 1H), 5.45 (s,
1H), 5.22 (dd, J=15.5, 8.1 Hz, 1H), 5.09 (t, J=9.8 Hz, 1H),
5.03-4.90 (m, 1H), 3.95 (s, 3H), 3.81 (s, 1H), 2.94-2.80 (m, 1H),
2.64 (dt, J=14.0, 7.0 Hz, 1H), 2.58-2.33 (m, 1H), 1.92-1.72 (m,
1H), 1.32 (d, J=6.2 Hz, 3H), 1.23 (dd, J=9.6, 2.8 Hz, 6H); ESIMS
m/z 489 ([M+H]
Example 9
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-8-(2-(methylsulfonylo-
xy)ethyl)-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00029##
[0129] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-hydroxyethyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate (660 mg, 1.58 mmol) in
CH.sub.2Cl.sub.2 (15 mL) at 0.degree. C. was added pyridine (750
mg, 9.48 mmol), followed by methanesulfonyl chloride (362 mg, 3.16
mmol). The resulting reaction mixture was warmed up to room
temperature (about 22.degree. C.) and stirred overnight. The
reaction mixture was partitioned between sat'd aqueous NaHCO.sub.3
solution (30 mL) and EtOAc (40 mL) and the phases were separated.
The aqueous phase was extracted with additional EtOAc (2.times.30
mL) and the combined EtOAc extracts were dried over
Na.sub.2SO.sub.4, filtered, and concentrated to dryness. The crude
residue was purified via column chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (660 mg, 84%)
as a white solid: .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 5.24
(s, 2H), 5.06 (t, J=9.8 Hz, 1H), 4.95-4.77 (m, 2H), 4.32-4.19 (m,
1H), 4.13-4.05 (m, 1H), 3.62 (s, 1H), 2.98 (s, 3H), 2.78 (dd,
J=14.9, 6.4 Hz, 1H), 2.62 (dt, J=13.9, 7.0 Hz, 1H), 2.25-2.08 (m,
1H), 1.83 (s, 1H), 1.47 (d, J=11.9 Hz, 9H), 1.28 (d, J=6.3 Hz, 3H),
1.21 (d, J=6.9 Hz, 6H); ESIMS m/z 496 ([M+H]
Example 9
Step 2: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-iodoethyl)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate
##STR00030##
[0131] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-8-(2
(methylsulfonyloxy)ethyl)-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
(350 mg, 0.71 mmol) in DMF (3 mL) at room temperature (about
22.degree. C.) was added NaI (1.06 g, 7.06 mmol), and the resulting
reaction mixture was heated to 60.degree. C. and stirred for 6 h.
The reaction mixture was partitioned between sat'd aqueous
NaHCO.sub.3 solution (20 mL) and EtOAc (25 mL) and the phases were
separated. The aqueous phase was extracted with EtOAc (2.times.25
mL) and the combined EtOAc extracts were dried over
Na.sub.2SO.sub.4, filtered, and concentrated to dryness. The crude
residue was purified via column chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (300 mg, 81%)
as a white solid: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
5.43-5.15 (m, 2H), 5.07 (t, J=9.8 Hz, 1H), 4.95-4.75 (m, 2H),
3.72-3.51 (m, 1H), 3.24 (ddd, J=10.6, 6.6, 4.3 Hz, 1H), 3.00-2.87
(m, 1H), 2.82 (td, J=10.9, 3.0 Hz, 1H), 2.62 (hept, J=7.0 Hz, 1H),
2.35-2.21 (m, 1H), 1.86-1.69 (m, 1H), 1.45 (s, 9H), 1.28 (d, J=6.3
Hz, 3H), 1.22 (dd, J=7.0, 3.9 Hz, 6H); ESIMS m/z 550
([M+Na].sup.+).
Example 9
Step 3:
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-ethyl-6-methyl-4,9-di-
oxo-1,5-dioxonan-7-yl isobutyrate
##STR00031##
[0133] To a solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-iodoethyl)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate (30 mg, 0.057 mmol) in benzene
(1.5 mL) was added Bu.sub.3SnH (27 mg, 0.091 mmol) and AIBN (1 mg)
at room temperature (about 22.degree. C.), and the reaction
solution was heated to reflux. After 1 h, the solution was cooled
to room temperature. The solvent was removed under vacuum and the
residue was purified via column chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (20 mg, 88%)
as a white solid: .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
5.44-5.19 (m, 2H), 5.03 (dd, J=13.0, 6.9 Hz, 1H), 4.91-4.73 (m,
2H), 3.70-3.52 (m, 1H), 2.68-2.52 (m, 1H), 2.45 (ddd, J=19.2, 12.0,
6.2 Hz, 1H), 1.71-1.56 (m, 2H), 1.45 (s, J=9.2 Hz, 9H), 1.26 (d,
J=6.2 Hz, 3H), 1.20 (d, J=7.0 Hz, 6H), 0.86 (t, J=7.4 Hz, 3H);
ESIMS m/z 424 ([M+Na].sup.+).
Example 9
Step 4: Preparation of
(3S,6S,7R,8R)-8-ethyl-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4,9-di-
oxo-1,5-dioxonan-7-yl isobutyrate (Compound 53)
##STR00032##
[0135] Compound 53 was prepared in the same manner as described in
Example 1, Step 5, Method A to give the title compound (83 mg, 41%)
as a white solid: mp 193-195.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.81 (s, 1H), 8.66 (d, J=8.1 Hz, 1H), 8.01 (d,
J=5.2 Hz, 1H), 6.89 (d, J=5.2 Hz, 1H), 5.47 (s, 1H), 5.20 (dd,
J=14.7, 8.1 Hz, 1H), 5.08 (t, J=9.9 Hz, 1H), 4.93 (dq, J=9.7, 6.3
Hz, 1H), 3.95 (s, 3H), 3.78 (m, 1H), 2.70-2.57 (m, 1H), 2.52 (ddd,
J=11.5, 7.4, 2.5 Hz, 1H), 1.81-1.63 (m, 2H), 1.53-1.34 (m, 2H),
1.29 (d, J=6.2 Hz, 3H), 1.21 (d, 6H), 0.88 (t, J=7.4 Hz, 3H); ESIMS
m/z 453 ([M+H]
Example 10
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-(4-(3-chlorophenyl)-1H-1,-
2,3-triazol-1-yl)ethyl)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl
isobutyrate
##STR00033##
[0137] To a solution
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-8-(2
(methylsulfonyloxy)ethyl)-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
(140 mg, 0.28 mmol) in DMF (3 mL) at room temperature (about
22.degree. C.) was added NaN.sub.3 (37 mg, 0.57 mmol). The
resulting reaction mixture was heated to 60.degree. C. and stirred
for 3 h. The reaction was partitioned between sat'd aqueous
NaHCO.sub.3 solution (20 mL) and EtOAc (25 mL) and the phases were
separated. The aqueous phase was extracted with additional EtOAc
(2.times.25 mL), and the combined EtOAc extracts were dried over
Na.sub.2SO.sub.4, filtered, and concentrated to dryness. The crude
residue was dissolved in DMF/H.sub.2O (1 mL/1 mL) and the resulting
solution was treated with 1-chloro-3-ethynylbenzene (39 mg, 0.28
mol), CuSO.sub.4 (4 mg, 0.025 mmol), and sodium ascorbate (22 mg,
0.11 mmol), and the reaction mixture was stirred at room
temperature overnight. The reaction was partitioned between sat'd
aqueous NaHCO.sub.3 solution (15 mL) and EtOAc (20 mL) and the
phases were separated. The aqueous phase was extracted with
additional EtOAc (2.times.20 mL), and the combined EtOAc extracts
were dried over Na.sub.2SO.sub.4, filtered, and concentrated to
dryness. The crude residue was purified via column chromatography
(SiO.sub.2, hexanes/EtOAc gradient) to afford the title compound
(105 mg, 64%) as a white solid: .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 7.82 (d, J=1.7 Hz, 1H), 7.70 (dq, J=3.2, 1.5 Hz, 2H), 7.33
(ddd, J=10.9, 8.0, 4.9 Hz, 2H), 5.40-5.15 (m, 2H), 5.08 (t, J=9.8
Hz, 1H), 4.82 (dd, J=14.6, 4.8 Hz, 2H), 4.51-4.24 (m, 2H), 3.63 (s,
1H), 2.66-2.49 (m, 2H), 2.42-2.25 (m, 1H), 2.14-2.00 (m, 1H), 1.45
(s, 9H), 1.27 (dd, J=6.7, 1.3 Hz, 3H), 1.18 (d, J=7.1 Hz, 6H);
ESIMS m/z 579 ([M+H]
Example 10
Step 2: Preparation of
(3S,6S,7R,8R)-8-(2-(4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-3-(3--
hydroxy-4 methoxypicolinamido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl
isobutyrate (Compound 54)
##STR00034##
[0139] Compound 54 was prepared in the same manner as described in
Example 1, Step 5, Method A to give the title compound (56 mg, 51%)
as a white solid: mp 222-224.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 11.75 (s, 1H), 8.64 (d, J=8.1 Hz, 1H), 8.01 (d,
J=5.2 Hz, 1H), 7.82 (s, 1H), 7.70 (d, J=7.6 Hz, 2H), 7.36 (dd,
J=13.8, 6.4 Hz, 2H), 6.90 (d, J=5.2 Hz, 1H), 5.46 (s, 1H), 5.21 (d,
J=8.1 Hz, 1H), 5.12 (t, J=9.7 Hz, 1H), 4.96-4.86 (m, 1H), 4.51-4.31
(m, 2H), 3.96 (s, 3H), 3.89-3.76 (m, 1H), 2.75-2.54 (m, 2H), 2.37
(s, 1H), 2.14 (s, 1H), 1.30 (d, J=6.2 Hz, 3H), 1.20 (d, J=7.0 Hz,
6H); ESIMS m/z 630 ([M+H]).
[0140] Compound 55 was made as described in Example 10.
Example 11
Preparation of
(3S,6S,7R,8R)-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-8-(2
(methylsulfonyloxy)ethyl)-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
(Compound 56)
##STR00035##
[0142] Compound 56 was prepared in the same manner as described in
Example 1, Step 5, Method A to give of a white solid (56 mg, 51%):
mp 153-155.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
11.76 (d, J=0.5 Hz, 1H), 8.65 (d, J=8.1 Hz, 1H), 8.02 (d, J=5.2 Hz,
1H), 6.90 (d, J=5.2 Hz, 1H), 5.47 (s, 1H), 5.20 (dd, J=15.2, 7.8
Hz, 1H), 5.16-5.05 (m, 1H), 4.96 (dq, J=9.8, 6.2 Hz, 1H), 4.28 (dt,
J=10.5, 5.3 Hz, 1H), 4.20-4.07 (m, 1H), 3.95 (s, 3H), 3.78 (d,
J=12.1 Hz, 1H), 2.98 (d, J=1.4 Hz, 3H), 2.89-2.82 (m, 1H), 2.63
(hept, J=7.0 Hz, 1H), 2.24-2.10 (m, J=11.2, 4.7 Hz, 1H), 1.94-1.79
(m, J=8.6, 5.8 Hz, 1H), 1.35-1.28 (m, 3H), 1.22 (dd, J=7.0, 0.9 Hz,
6H); ESIMS m/z 547 ([M+H]
Example 12
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-8-phenethyl-
-1,5-dioxonan-7-yl isobutyrate
##STR00036##
[0144] To an oven-dried flask containing a magnetic stir bar was
added freshly ground zinc dust (149 mg, 2.28 mmol) and a small
volume of DMF (100 .mu.L) was added to just cover the dust. Iodine
(57 mg, 0.23 mmol) was added and the mixture stirred for 2 min and
then warmed to 40.degree. C. A solution of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-iodoethyl)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate (200 mg, 0.38 mmol) in DMF (1
mL) was added slowly at 40.degree. C. After 15 min, the reaction
mixture was cooled to ambient temperature (about 22.degree. C.),
and a solution of Pd((o-tol).sub.3P).sub.2Cl.sub.2 (7.5 mg, 0.01
mmol) and 1-fluoro-4-iodobenzene (58 uL, 0.49 mmol) in DMF (900
.mu.L) was added to the reaction and the reaction was warmed back
to 40.degree. C. and stirring continued for 2.5 h. The mixture was
cooled, diluted with EtOAc (2 mL) and filtered through a 0.45
fritted filter disc. The filtrate was diluted with EtOAc (20 mL),
washed with saturated NaHCO.sub.3 solution (15 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated. Purification by
column chromatography (SiO.sub.2, hexanes/EtOAc gradient) gave the
title compound (92 mg, 51%) as a white glassy solid: .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 7.31-7.14 (m, 3H), 7.14-7.04 (m, 2H),
5.46-5.15 (m, 2H), 5.06 (t, J=9.9 Hz, 1H), 4.91-4.72 (m, 2H), 3.61
(s, 1H), 2.76-2.48 (m, 3H), 2.40 (dt, J=13.8, 8.2 Hz, 1H),
2.17-1.99 (m, 1H), 1.73-1.52 (m, 1H), 1.45 (s, 9H), 1.25 (d, J=6.3
Hz, 3H), 1.16 (d, J=7.0 Hz, 6H); ESIMS m/z 500 ([M+Na].sup.+).
Example 12
Step 2: Preparation of
(3S,6S,7R,8R)-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4,9-dioxo-8-ph-
enethyl-1,5-dioxonan-7-yl isobutyrate (Compound 57)
##STR00037##
[0146] Compound 57 was prepared in the same manner as described in
Example 1, Step 5, Method A to give a white solid (56 mg, 55%): mp
183-184.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 11.80
(s, 1H), 8.66 (d, J=8.1 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 7.34-7.15
(m, 3H), 7.15-7.02 (m, 2H), 6.89 (d, J=5.2 Hz, 1H), 5.50 (s, 1H),
5.21 (dd, J=15.1, 7.6 Hz, 1H), 5.10 (t, J=9.9 Hz, 1H), 4.96-4.83
(m, 1H), 3.95 (s, 3H), 3.80 (s, 1H), 2.78-2.51 (m, 3H), 2.51-2.35
(m, 1H), 2.21-2.06 (m, 1H), 1.73-1.58 (m, 1H), 1.28 (d, J=6.2 Hz,
3H), 1.18 (d, J=7.0 Hz, 6H); ESIMS m/z 529 ([M+H]
[0147] Compounds 58 and 59 were made as described in Example
12.
Example 13
Step 1: Preparation of
(3S,6S,7R,8R)-8-(2-(benzyloxy)ethyl)-3-(tert-butoxycarbonylamino)-6-methy-
l-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00038##
[0149] A mixture of 2-benzyloxy-1-methylpyridinium triflate (255
mg, 0.73 mmol), .alpha.,.alpha.,.alpha.-trifluorotoluene
(PhCF.sub.3, 0.75 mL), MgO (30 mg, 0.74 mmol), and
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(2-hydroxyethyl)-6-methyl-4,-
9-dioxo-1,5-dioxonan-7-yl isobutyrate (150 mg, 0.36 mmol) was
heated at 83.degree. C. for 1 day (d). The reaction mixture was
cooled to room temperature (about 22.degree. C.) and filtered
through Celite.RTM.. The filtrate was concentrated under vacuum and
purified by column chromatography (SiO.sub.2, hexanes/EtOAc
gradient) to afford the title compound (66 mg, 36%): .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 7.40-7.21 (m, 5H), 5.28 (m, 2H), 5.06
(t, J=10.0 Hz, 1H), 4.95-4.73 (m, 2H), 4.69 (s, 2H), 4.42 (s, 2H),
3.52-3.33 (m, 3H), 2.77 (td, J=11.5, 2.8 Hz, 1H), 2.60 (dq, J=14.0,
7.0 Hz, 1H), 1.42 (s, 9H), 1.26 (d, J=6.2 Hz, 3H), 1.19 (dd, J=7.0,
2.5 Hz, 6H); ESIMS m/z 530 ([M+Na]
Example 13
Step 2: Preparation of
(3S,6S,7R,8R)-8-(2-(benzyloxy)ethyl)-3-(3-hydroxy-4-methoxypicolinamido)--
6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 60)
##STR00039##
[0151] Compound 60 was prepared in the same manner as described in
Example 1, Step 5, Method A to give a white solid (32 mg, 46%): mp
139-140.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 11.81
(s, 1H), 8.65 (d, J=8.3 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 7.40-7.23
(m, 5H), 6.89 (d, J=5.2 Hz, 1H), 5.50-5.30 (m, 1H), 5.28-5.05 (m,
2H), 5.03-4.87 (m, 1H), 4.44 (s, 2H), 3.95 (s, 3H), 3.71 (s, 1H),
3.57-3.34 (m, 2H), 2.83 (td, J=11.5, 2.8 Hz, 1H), 2.61 (hept, J=7.0
Hz, 1H), 2.15-1.98 (m, 1H), 1.78-1.56 (m, 1H), 1.29 (d, J=6.2 Hz,
3H), 1.21 (d, J=7.0 Hz, 6H); ESIMS m/z 559 ([M+H].sup.+).
Example 14
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-8-(cyclohexylmethyl)-6-methyl--
4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
##STR00040##
[0153] To a 50 mL high pressure reactor with a magnetic stir bar
was added
(3S,6S,7R,8R)-8-benzyl-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-1,-
5-dioxonan-7-yl isobutyrate (400 mg, 0.863 mmol) in THF (3 mL) to
give a colorless solution. To the solution was added 5% Rh/C (50
mg, 0.024 mmol). After the reactor was sealed, it was purged with
hydrogen gas (4 times). The reactor was charged to approximately
600 psi of H.sub.2 at room temperature (about 22.degree. C.) and
then the reaction was warmed to 70.degree. C. and stirred at for 6
h. The reaction mixture was cooled, filtered, and concentrated. The
residue was purified via column chromatography (SiO.sub.2,
hexanes/EtOAc gradient) to afford the title compound (414 mg, 92%)
as an off-white solid: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
5.32 (dd, J=39.3, 12.3 Hz, 2H), 5.01 (t, J=9.9 Hz, 1H), 4.94-4.72
(m, 2H), 3.58 (s, J=51.8 Hz, 1H), 2.72-2.51 (m, 2H), 1.78-1.52 (m,
6H), 1.45 (s, J=6.0 Hz, 9H), 1.26 (d, J=6.3 Hz, 3H), 1.20 (dd,
J=7.0, 3.0 Hz, 6H), 1.19-1.04 (m, 4H), 1.02-0.68 (m, 3H); .sup.13C
NMR (101 MHz, CDCl.sub.3) .delta. 175.50, 172.74, 154.78, 133.68,
123.39, 80.39, 75.22, 74.50, 67.85, 65.49, 51.47, 47.36, 35.85,
35.40, 34.05, 34.01, 32.09, 28.19, 26.28, 26.00, 25.87, 18.95,
18.82, 17.77; ESIMS m/z 492 ([M+Na].sup.+).
Example 14
Step 2: Preparation of
(3S,6S,7R,8R)-8-(cyclohexylmethyl)-3-(3-hydroxy-4-methoxypicolinamido)-6--
methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 61)
##STR00041##
[0155] Compound 61 was prepared in the same manner as described in
Example 1, Step 5, Method A to give a white solid (175 mg, 48%): mp
188-189.degree. C.; .sup.1HNMR (300 MHz, CDCl.sub.3) .delta. 11.81
(s, 1H), 8.66 (d, J=8.0 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 6.89 (d,
J=5.2 Hz, 1H), 5.48 (s, 1H), 5.18 (s, 1H), 5.05 (t, J=9.8 Hz, 1H),
4.99-4.87 (m, 1H), 3.95 (s, 3H), 3.76 (s, 1H), 2.70 (t, J=10.1 Hz,
1H), 2.60 (dd, J=14.0, 7.0 Hz, 1H), 1.79-1.59 (m, 6H), 1.28 (d,
J=6.2 Hz, 3H), 1.21 (dd, J=7.0, 2.3 Hz, 6H), 1.16 (d, J=7.0 Hz,
4H), 1.02-0.69 (m, 3H); ESIMS m/z 521 ([M+H].sup.+).
[0156] Compound 62 was made as described in Example 14.
Example 15
Preparation of
(3S,6S,7R,8R)-8-heptyl-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4,9-d-
ioxo-1,5-dioxonan-7-yl isobutyrate (Compound 63)
##STR00042##
[0158]
(3S,6S,7R,8R)-8-((E)-hept-2-enyl)-3-(3-hydroxy-4-methoxypicolinamid-
o)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (163 mg, 0.31
mmol) was dissolved in EtOAc (15 mL) and passed through an
H-Cube.RTM. Continuous Flow hydrogenator equipped with a 10% Pd/C
cartridge (full H.sub.2, 80.degree. C., 1 mL/min flow rate). The
resulting solution was concentrated in vacuo to give the title
compound (162 mg, 99%) as a white solid: mp 131-134.degree. C.; IR
(neat) 3341, 1739, 1654, 1141 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 11.81 (s, 1H), 8.66 (d, J=8.1 Hz, 1H), 8.01 (d,
J=5.2 Hz, 1H), 6.89 (d, J=5.2 Hz, 1H), 5.19 (m, 1H), 5.14-5.02 (m,
1H), 5.02-4.87 (m, 1H), 3.95 (s, 3H), 3.87-3.69 (m, 1H), 2.70-2.52
(m, 2H), 1.80-1.66 (m, 1H), 1.43-1.08 (m, 21H), 0.86 (t, J=6.8 Hz,
3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 175.59, 172.71,
169.77, 169.00, 155.47, 148.87, 140.74, 129.98, 109.74, 75.20,
74.94, 65.12, 56.16, 50.07, 34.13, 31.70, 29.25, 28.98, 28.40,
27.09, 22.62, 18.98, 18.97, 17.82, 14.08; ESIMS m/z 523.4
([M+H]
[0159] Compound 64 was made as described in Example 15.
Example 16
Step 1: Preparation of
(3S,6S,7R,8R)-3-(tert-butoxycarbonylamino)-6-methyl-4,9-dioxo-8-((pyridin-
-2-ylthio)methyl)-1,5-dioxonan-7-yl isobutyrate
##STR00043##
[0161] To a solution of
2-((3S,7R,8R,9S)-3-(tert-butoxycarbonylamino)-8-(isobutyryloxy)-9-methyl--
2,6-dioxo-1,5-dioxonan-7-yl)acetic acid (500 mg, 1.2 mmol) in
anhydrous THF (7 mL) at -15.degree. C. was added N-methylmorpholine
(127 .mu.L, 1.2 mmol) and isobutylchloroformate (152 .mu.L, 1.2
mmol). The mixture was stirred for 5 min and then treated with a
solution of 2-mercaptopyridine N-oxide (177 mg, 1.4 mmol) and TEA
(162 .mu.L, 1.2 mmol) in THF (2 mL). The reaction was stirred at
-15.degree. C. in the dark (covered with aluminum foil) for 1 h.
The reaction was then filtered, concentrated, and the resulting
bright yellow residue dissolved in CH.sub.2Cl.sub.2 (5 mL) and
irradiated for 1 hr. The crude reaction mixture was concentrated
and purified by flash chromatography (SiO.sub.2, 10% EtOAc/hexanes)
to furnish the title compound (169 mg, 29%) as a fluffy white
solid: mp 54-58.degree. C.; IR (neat) 3370, 2980, 2939, 2878, 1753,
1718 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.35 (d,
J=4.9 Hz, 1H), 7.48-7.41 (m, 1H), 7.11 (d, J=8.0 Hz, 1H), 7.00-6.94
(m, 1H), 5.32 (bs, J=12.9 Hz, 1H), 5.21-5.07 (m, 2H), 4.87 (dt,
J=16.1, 6.4 Hz, 2H), 3.66-3.60 (m, 1H), 3.59 (bs, 1H), 3.15-3.00
(m, 2H), 2.68 (dq, J=14.2, 7.1 Hz, 1H), 1.43 (s, 9H), 1.33-1.25 (m,
9H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 176.11, 171.91,
171.33, 157.67, 155.07, 149.73, 136.35, 122.89, 120.10, 81.00,
75.34, 74.76, 66.22, 51.66, 51.26, 34.68, 28.74, 28.64 (3), 19.38,
19.23, 18.14; ESIMS m/z 519 ([M+Na].sup.+).
Example 16
Step 2: Preparation of
(3S,6S,7R,8R)-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4,9-dioxo-8-((-
pyridin-2-ylthio)methyl)-1,5-dioxonan-7-yl isobutyrate (Compound
65)
##STR00044##
[0163] Compound 65 was prepared in the same manner as described in
Example 1, Step 5, Method B to give a white solid (115 mg, 70%): mp
148-150.degree. C.; IR (neat) 3356, 2976, 2943, 1742, 1653
cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.81 (s, 1H),
8.61 (d, J=8.4 Hz, 1H), 8.41-8.36 (m, 1H), 8.01 (d, J=5.2 Hz, 1H),
7.51-7.44 (m, 1H), 7.17-7.12 (m, 1H), 7.01 (ddd, J=7.2, 4.9, 1.0
Hz, 1H), 6.90 (d, J=5.2 Hz, 1H), 5.50 (bs, 1H), 5.29-5.13 (m, 2H),
4.97 (dd, J=9.8, 6.2 Hz, 1H), 3.97 (s, 3H), 3.68 (m, 2H), 3.16 (t,
J=9.4 Hz, 2H), 2.73 (dt, J=14.0, 7.1 Hz, 1H), 1.38-1.28 (m, 9H);
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 176.21, 172.00, 170.30,
169.38, 157.47, 155.81, 149.78, 149.19, 141.19, 136.46, 130.27,
122.94, 120.20, 110.13, 75.08, 65.47, 56.59, 51.20, 50.09, 39.06,
34.70, 28.67, 19.45, 19.28, 18.19; ESIMS m/z 548 ([M+H]
Example 17
Preparation of
(3S,6S,7R,8R)-3-(3-acetoxy-4-methoxypicolinamido)-8-(cyclohexylmethyl)-6--
methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (Compound 66)
##STR00045##
[0165] Acetyl chloride (9 .mu.L, 0.125 mmol) was added to a
solution of
(3S,6S,7R,8R)-8-(cyclohexylmethyl)-3-(3-hydroxy-4-methoxypicolinamido)-6--
methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate (50 mg, 0.100 mmol)
and pyridine (40 .mu.L, 0.480 mmol) in CH.sub.2Cl.sub.2 (1 mL), and
the reaction was stirred at ambient temperature (about 22.degree.
C.) overnight. The solution was loaded directly onto a pre-packed
SiO.sub.2 column for purification by column chromatography (030%
EtOAc/CH.sub.2Cl.sub.2) to afford the title compound (28 mg, 52%)
as a white solid: mp 164-170.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.70 (d, J=7.5 Hz, 1H), 8.35 (d, J=5.4 Hz, 1H),
7.03 (d, J=5.5 Hz, 1H), 5.47 (br s, 1H), 5.25-5.11 (m, 1H), 5.03
(t, J=9.9 Hz, 1H), 4.97-4.84 (m, 1H), 3.92 (s, 3H), 3.72 (br s,
1H), 2.69 (dd, J=16.8, 7.0 Hz, 1H), 2.60 (sept, J=14.0, 7.0 Hz,
1H), 2.40 (s, 3H), 1.83-1.54 (m, 6H), 1.36-1.02 (m, 14H), 0.94-0.67
(m, 2H); HRMS-ESI (m/z): calcd for C.sub.28H.sub.38N.sub.2O.sub.10,
562.2526. found, 562.2516.
[0166] Compounds 67-70 were made as described in Example 17.
Example 18
Evaluation of Fungicidal Activity: Leaf Blotch of Wheat
(Mycosphaerella graminicola; anamorph: Septoria tritici; Bayer code
SEPTTR)
[0167] Wheat plants (variety Yuma) were grown from seed in a
greenhouse in 50% mineral soil/50% soil-less Metro mix until the
first leaf was fully emerged, with 7-10 seedlings per pot. These
plants were inoculated with an aqueous spore suspension of Septoria
tritici either prior to or after fungicide treatments. After
inoculation the plants were kept in 100% relative humidity (one day
in a dark dew chamber followed by two to three days in a lighted
dew chamber) to permit spores to germinate and infect the leaf. The
plants were then transferred to a greenhouse at 20.degree. C. for
disease to develop.
Example 19
Evaluation of Fungicidal Activity: Wheat Brown Rust (Puccinia
triticina. Synonym: Puccinia recondite f sp. tritici; Bayer code
PUCCRT)
[0168] Wheat plants (variety Yuma) were grown from seed in a
greenhouse in 50% mineral soil/50% soil-less Metro mix until the
first leaf was fully emerged, with 7-10 seedlings per pot. These
plants were inoculated with an aqueous spore suspension of Puccinia
recondite f sp. tritici either prior to or after fungicide
treatments. After inoculation the plants were kept in 100% relative
humidity overnight to permit spores to germinate and infect the
leaf. The plants were then transferred to a greenhouse set at 24 C
for disease to develop.
TABLE-US-00001 TABLE 1 Compound Structure and Appearance Compound
Number Appearance Structure 1 White Solid ##STR00046## 2 Yellow
Solid ##STR00047## 3 Dark Brown Solid ##STR00048## 4 White Solid
##STR00049## 5 Yellow Solid ##STR00050## 6 White Solid ##STR00051##
7 White Solid ##STR00052## 8 Thick Oil ##STR00053## 9 White Solid
##STR00054## 10 White Solid ##STR00055## 11 White Solid
##STR00056## 12 White Solid ##STR00057## 13 White Solid
##STR00058## 14 White Solid ##STR00059## 15 White Solid
##STR00060## 16 White Solid ##STR00061## 17 Tan Solid ##STR00062##
18 White Solid ##STR00063## 19 Off White Solid ##STR00064## 20
Yellow Oil ##STR00065## 21 Glassy Solid ##STR00066## 22 White Solid
##STR00067## 23 Yellow Solid ##STR00068## 24 White Solid
##STR00069## 25 White Solid ##STR00070## 26 White Solid
##STR00071## 27 White Solid ##STR00072## 28 Sticky Solid
##STR00073## 29 Sticky Colorless Solid ##STR00074## 30 White
Semi-Solid ##STR00075## 31 Sticky Oil ##STR00076## 32 White Solid
##STR00077## 33 Yellow Oil ##STR00078## 34 White Foam ##STR00079##
35 White Solid ##STR00080## 36 Glassy Solid ##STR00081## 37 White
Solid ##STR00082## 38 Pale Solid ##STR00083## 39 White Solid
##STR00084## 40 White Solid ##STR00085## 41 Sticky Solid
##STR00086## 42 White Solid ##STR00087## 43 White Solid
##STR00088## 44 White Solid ##STR00089## 45 White Solid
##STR00090## 46 White Solid ##STR00091## 47 White Solid
##STR00092## 48 White Solid ##STR00093## 49 White Solid
##STR00094## 50 White Solid ##STR00095## 51 White Solid
##STR00096## 52 White Solid ##STR00097## 53 White Solid
##STR00098## 54 White Solid ##STR00099## 55 White Solid
##STR00100## 56 White Solid ##STR00101## 57 White Solid
##STR00102## 58 White Solid ##STR00103## 59 Glassy Solid
##STR00104## 60 White Solid ##STR00105## 61 White Solid
##STR00106## 62 White Solid ##STR00107## 63 White Solid
##STR00108## 64 White Solid ##STR00109## 65 White Solid
##STR00110## 66 White Solid ##STR00111## 67 White Solid
##STR00112## 68 White Solid ##STR00113## 69 White Solid
##STR00114## 70 White Solid ##STR00115##
TABLE-US-00002 TABLE 2 Analytical Data Compound MP IR Number
(.degree. C.) (cm.sup.-1) MASS .sup.lH NMR* .sup.13C NMR* 1 208- --
ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 210 m/z 532.9 11.77 (s, 1
H), 8.59 (d, J = ([M + H].sup.+) 8.2 Hz, 1 H), 7.99 (d, J = 5.2 Hz,
1 H), 7.17- 7.04 (m, 2 H), 6.95 (dd, J = 12.0, 5.3 Hz, 2 H), 6.88
(d, J = 5.2 Hz, 1 H), 5.33 (m, 1 H), 5.20 (m, 2 H), 4.98 (m, 1 H),
3.94 (s, 3 H), 3.63 (m, 1 H), 2.92 (m, 2 H), 2.74- 2.57 (m, 2 H),
1.32 (d, J = 6.3 Hz, 3 H), 1.25 (m, 6 H) 2 148- -- ESIMS .sup.1H
NMR (DMSO-d.sub.6) .delta. -- 155 m/z 516.0 9.52 (d, J = 6.9 Hz, 1
H), ([M + H].sup.+) 8.47-8.35 (m, 2 H), 8.09 (d, J = 5.2 Hz, 1 H),
7.62 (d, J = 7.9 Hz, 1 H), 7.31 (dd, J = 7.8, 4.8 Hz, 1 H), 7.23
(d, J = 5.3 Hz, 1 H), 5.09-4.79 (m, 4 H), 4.34 (m, 1 H), 3.89 (s, 3
H), 3.21 (m, 1 H), 2.83-2.59 (m, 3 H), 1.24 (d, J = 6.2 Hz, 3 H),
1.17 (d, J = 7.0 Hz, 6 H) 3 92- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. -- 95 m/z 516.9 11.81 (s, 1 H), 8.63 (d, J = ([M +
H].sup.+) 8.1 Hz, 1 H), 8.51(m, 1 H), 8.01 (d, J = 5.2 Hz, 1 H),
7.58 (td, J = 7.6, 1.8 Hz, 1 H), 7.19-7.06 (m, 2 H), 6.89 (d, J =
5.2 Hz, 1 H), 5.46-5.10 (m, 3 H), 5.02 (m, 1 H), 3.95 (s, 3 H),
3.71 (m, 1 H), 3.48-3.31 (m, 1 H), 3.23 (dd, J = 14.4, 11.4 Hz, 1
H), 2.90 (dd, J = 14.4, 3.5 Hz, 1 H), 2.62 (m, 1 H), 1.35 (d, J =
6.3 Hz, 3 H), 1.23 (d, J = 7.1 Hz, 6 H) 4 175- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. -- 179 m/z 528.9 11.79 (s, 1 H), 8.59 (d, J =
([M + H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1 H), 7.04 (dd,
J = 21.3, 8.0 Hz, 4 H), 6.88 (d, J = 5.2 Hz, 1 H), 5.42-5.27 (m, 1
H), 5.19 (m, 2 H), 5.08- 4.87 (m, 1 H), 3.94 (s, 3 H), 3.62 (m, 1
H), 2.93 (m, 2 H), 2.76-2.55 (m, 2 H), 1.32 (d, J = 6.3 Hz, 3 H),
1.24 (d, J = 7.0 Hz, 6 H) 5 151- -- ESIMS .sup.1H NMR
(DMSO-d.sub.6) .delta. -- 156 m/z 517.6 11.95 (s, 1 H), 9.55 (s,
([M + H].sup.+) 1 H), 8.49 (d, J = 5.7 Hz, 2 H), 8.22 (d, J = 7.7
Hz, 1 H), 8.06 (s, 1 H), 7.29 (d, J = 5.9 Hz, 2 H), 7.22 (m, 1 H),
6.98 (d, J = 7.7 Hz, 1 H), 5.07-4.80 (m, 4 H), 4.32 (m, 1 H), 3.89
(s, 3 H), 3.52-3.22 (m, 2 H), 2.94-2.72 (m, 4 H), 2.66 (m, 1 H),
1.24 (d, J = 6.1 Hz, 3 H), 1.15 (m, 6 H) 6 222- -- ESIMS .sup.1H
NMR (CDCl.sub.3) .delta. -- 226 m/z 583.0 11.76 (s, 1 H), 8.59 (d,
J = ([M + H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1 H), 7.52
(d, J = 8.1 Hz, 2 H), 7.25 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 5.2
Hz, 1 H), 5.33 (m, 1 H), 5.21 (m, 2 H), 4.99 (m, 1 H), 3.94 (s, 3
H), 3.63 (m, 1 H), 2.99 (m, 2 H), 2.75 (d, J = 12.7 Hz, 1 H), 2.63
(m, 1 H), 1.33 (d, J = 6.3 Hz, 3 H), 1.25 (d, J = 7.0 Hz, 6 H) 7
148- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 152 m/z 550.0
11.78 (s, 1 H), 8.64 (d, J = ([M + H].sup.+) 6.3 Hz, 1 H), 8.18 (d,
J = 2.3 Hz, 1 H), 8.00 (d, J = 5.2 Hz, 1 H), 7.44 (dd, J = 8.2, 2.5
Hz, 1 H), 7.29-7.20 (m, 1 H), 6.89 (d, J = 5.3 Hz, 1 H), 5.33 (m, 1
H), 5.32- 4.99 (m, 3 H), 4.96 (m, 1 H), 3.95 (s, 3 H), 3.92- 3.46
(m, 2 H), 3.11- 2.84 (m, 2 H), 2.84- 2.56 (m, 2 H), 1.33 (d, J =
6.3 Hz, 3 H), 1.25 (d, J = 7.0 Hz, 6 H) 8 -- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. -- m/z 544.9 11.86 (s, 1 H), 8.72 (d, J = ([M
+ H].sup.+) 7.5 Hz, 1 H), 8.01 (d, J = 5.1 Hz, 1 H), 7.06 (d, J =
8.6 Hz, 2 H), 6.91 (d, J = 5.0 Hz, 1 H), 6.85- 6.75 (m, 2 H), 5.36
(m, 1 H), 5.21 (m, 2 H), 4.99 (m, 1 H), 3.97 (s, 3 H), 3.78 (s, 3
H), 3.66 (m, 1 H), 2.91 (m, 2 H), 2.65 (m, 2 H), 1.34 (d, J = 6.3
Hz, 3 H), 1.26 (m, 6 H) 9 192- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. -- 194 m/z 551.0 11.77 (s, 1 H), 8.61 (d, J = ([M +
H].sup.+) 8.1 Hz, 1 H), 8.01 (d, J = 3.1 Hz, 1 H), 7.26 (m, 2 H),
7.16-7.03 (m, 2 H), 6.89 (d, J = 5.1 Hz, 1 H), 5.34 (m, 1 H), 5.21
(m, 2 H), 5.10-4.68 (m, 1 H), 3.96 (s, 3 H), 3.81- 3.56 (m, 1 H),
3.21- 2.76 (m, 2 H), 2.76- 2.52 (m, 2 H), 1.34 (d, J = 6.3 Hz, 3
H), 1.26 (d, J = 6.9 Hz, 6 H) 10 184- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. -- 185 m/z 550.9 11.77 (s, 1 H), 8.59 (d, J =
([M + H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1 H), 7.12 (m, 1
H), 6.88 (d, J = 5.2 Hz, 1 H), 6.84-6.70 (m, 2 H), 5.33 (m, 1 H),
5.19 (m, 2 H), 5.08-4.89 (m, 1 H), 3.94 (s, 3 H), 3.67- 3.57 (m, 1
H), 3.02- 2.72 (m, 3 H), 2.66 (m, 1 H), 1.33 (d, J = 6.3 Hz, 3 H),
1.25 (m, 6 H) 11 186- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. --
191 m/z 564.8 11.76 (s, 1 H), 8.64 (d, J = ([M + H].sup.+) 8.2 Hz,
1 H), 8.02 (d, J = 5.2 Hz, 1 H), 6.90 (d, J = 5.2 Hz, 1 H), 5.49
(m, 1 H), 5.22 (m, 1 H), 5.04 (t, J = 9.8 Hz, 1 H), 4.99- 4.80 (m,
1 H), 3.96 (s, 3 H), 3.87 (m, 1 H), 3.34 (dd, J = 11.8, 9.6 Hz, 1
H), 3.16-2.97 (m, 2 H), 2.64 (m, 1 H), 1.30 (d, J = 6.2 Hz, 3 H),
1.23 (d, J = 7.0 Hz, 6 H) 12 214- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. -- 216 m/z 591.0 11.79 (s, 1 H), 8.60 (d, J = ([M +
H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1 H), 7.58- 7.53 (m, 2
H), 7.52- 7.47 (m, 2 H), 7.42 (dd, J = 10.4, 4.8 Hz, 2 H), 7.32 (m,
1 H), 7.20 (d, J = 8.2 Hz, 2 H), 6.87 (d, J = 5.3 Hz, 1 H), 5.36
(m, 1 H), 5.31-5.10 (m, 2 H), 5.00 (m, 1 H), 3.94 (s, 3 H), 3.63
(m, 1 H), 3.10-2.88 (m, 2 H), 2.75 (d, J = 12.0 Hz, 1 H), 2.64 (m,
1 H), 1.34 (d, J = 6.3 Hz, 3 H), 1.25 (m, 6 H) 13 182- -- ESIMS
.sup.1H NMR (CDCl.sub.3) .delta. -- 186 m/z 591.0 11.78 (s, 1 H),
8.60 (d, J = ([M + H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1
H), 7.61- 7.51 (m, 2 H), 7.43 (m, 3 H), 7.40-7.29 (m, 3 H), 7.12
(d, J = 7.6 Hz, 1 H), 6.87 (d, J = 5.2 Hz, 1 H), 5.35 (m, 1 H),
5.24 (m, 2 H), 5.00 (m, 1 H), 3.94 (s, 3 H), 3.63 (m, 1 H),
3.14-2.95 (m, 2 H), 2.78 (m, 1 H), 2.64 (m, 1 H), 1.34 (d, J = 6.3
Hz, 3 H), 1.24 (d, J = 7.0 Hz, 6 H) 14 169- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. 9.21- -- 175 m/z 517.0 8.53 (m, 4 H), 8.04 (d,
([M + H].sup.+) J = 5.2 Hz, 1 H), 7.18 (d, J = 5.3 Hz, 1 H), 5.40-
5.23 (m, 1 H), 5.16 (m, 2 H), 5.08-4.87 (m, 1 H), 4.20-4.06 (m, 1
H), 3.96 (s, 3 H), 3.35- 3.17 (m, 1 H), 2.94 (m, 2 H), 2.86-2.66
(m, 1 H), 1.35 (d, J = 6.3 Hz, 3 H), 1.26 (d, J = 7.0 Hz, 6 H) 15
192- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 197 m/z 564.9)
11.78 (s, 1 H), 8.55 (d, J = ([M + H].sup.+) 8.0 Hz, 1 H), 7.96 (d,
J = 5.2 Hz, 1 H), 7.92 (d, J = 8.2 Hz, 1 H), 7.85 (d, J = 7.9 Hz, 1
H), 7.73 (d, J = 8.0 Hz, 1 H), 7.59- 7.44 (m, 2 H), 7.41- 7.29 (m,
2 H), 6.86 (d, J = 5.2 Hz, 1 H), 5.44- 5.23 (m, 2 H), 5.18 (m, 1
H), 5.02 (m, 1 H), 3.93 (s, 3 H), 3.59-3.46 (m, 1 H), 3.45-3.24 (m,
2 H), 3.17 (m, 1 H), 2.81- 2.70 (m, 1 H), 1.37 (d, J = 6.3 Hz, 3
H), 1.32 (d, J = 6.6 Hz, 6 H) 16 188- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. -- 190 m/z 584.3 11.77 (s, 1 H), 8.60 (d, J =
([M + H].sup.+) 8.1 Hz, 1 H), 7.99 (d, J = 5.2 Hz, 1 H), 7.48- 7.34
(m, 4 H), 6.88 (d, J = 5.2 Hz, 1 H), 5.34 (m, 1 H), 5.28-5.10 (m, 2
H), 4.99 (dq, J = 12.4, 6.2 Hz, 1 H), 3.94 (s, 3 H), 3.69-3.57 (m,
1 H), 3.13-3.00 (m, 1 H), 3.00-2.90 (m, 1 H), 2.75 (d, J = 12.2 Hz,
1 H), 2.64 (m, 1 H), 1.34 (d, J = 6.3 Hz, 3 H), 1.25 (d, J = 7.0
Hz, 6 H) 17 161- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 165
m/z 465.6 11.80 (s, 1 H), 8.65 (d, J = ([M + H].sup.+) 8.2 Hz, 1
H), 8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.68
(ddt, J = 17.1, 10.2, 6.7 Hz, 1 H), 5.46 (m, 1 H), 5.20
(dd, J = 14.8, 7.7 Hz, 1 H), 5.16-5.01 (m, 3 H), 5.01-4.90 (m, 1
H), 3.95 (s, 3 H), 3.78 (m, 1 H), 2.76-2.54 (m, 2 H), 2.53-2.40 (m,
1 H), 2.14 (m, 1 H), 1.30 (d, J = 6.3 Hz, 3 H), 1.22 (d, J = 7.0
Hz, 6 H) 18 146- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 148
m/z 521.4 11.81 (s, 1 H), 8.65 (d, J = ([M + H].sup.+) 8.1 Hz, 1
H), 8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.47 (m,
2 H), 5.23 (m, 2 H), 5.10 (dd, J = 11.9, 7.9 Hz, 1 H), 5.00-4.88
(m, 1 H), 3.95 (s, 3 H), 3.74 (m, 1 H), 2.70-2.56 (m, 2 H),
2.48-2.31 (m, 1 H), 2.06 (m, 1 H), 1.95 (q, J = 6.6 Hz, 2 H), 1.37-
1.24 (m, 7 H), 1.23- 1.19 (m, 6 H), 0.86 (t, J = 7.1 Hz, 3 H) 19
48- -- ESIMS .sup.1H NMR (300 MHz, -- 50 m/z 673 CDCl.sub.3)
.delta. 8.55 (d, J = ([M + H].sup.+) 7.9 Hz, 1 H), 8.26 (d, J = 5.5
Hz, 1 H), 8.04-7.87 (m, 2 H), 7.55 (t, J = 7.4 Hz, 1 H), 7.43 (t, J
= 7.5 Hz, 2 H), 6.95 (d, J = 5.4 Hz, 1 H), 5.85-5.62 (m, 2 H), 5.41
(s, 1 H), 5.26- 5.06 (m, 2 H), 4.94 (dd, J = 9.8, 6.3 Hz, 1 H),
4.42-4.19 (m, 2 H), 3.92 (d, J = 14.3 Hz, 3 H), 3.65 (s, 1 H), 2.76
(t, J = 9.5 Hz, 1 H), 2.62 (dt, J = 10.8, 5.5 Hz, 1 H), 2.58-2.47
(m, 1 H), 2.30 (s, 1 H), 1.82 (s, 1 H), 1.29 (d, J = 6.3 Hz, 3 H),
1.21 (dd, J = 7.0, 0.9 Hz, 6 H), 1.13 (d, J = 7.0 Hz, 6 H) 20 -- --
ESIMS .sup.1H MR (CDCl.sub.3) .delta. 8.53 .sup.13C NMR m/z 633.4
(d, J = 7.9 Hz, 1 H), 8.27 (CDCl.sub.3) .delta. ([M + H].sup.+) (d,
J = 5.4 Hz, 1 H), 7.09 176.33, 175.61, (m, 2 H), 6.95 (m, 3 H),
171.67, 163.17, 5.74 (d, J = 1.1 Hz, 2 H), 160.25, 145.63, 5.35 (m,
1 H), 5.19 (m, 144.40, 141.39, 2 H), 5.01-4.88 (m, 133.57, 130.34,
1 H), 3.89 (s, 3 H), 3.63 130.26, 115.56, (m, 1 H), 3.02-2.80 (m,
115.35, 109.83, 2 H), 2.73-2.47 (m, 89.68, 75.04, 3 H), 1.31 (d, J
= 6.3 Hz, 74.41, 65.75, 3 H), 1.26-1.18 (m, 56.20, 52.20, 6 H),
1.13 (d, J = 7.0 Hz, 50.39, 34.13, 6 H) 33.86, 19.00, 18.68, 18.53,
17.85 21 -- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. 8.53 m/z
651.5 (d, J = 7.9 Hz, 1 H), 8.28 ([M + H].sup.+) (d, J = 5.2 Hz, 1
H), 7.12 (m, 1 H), 6.97 (d, J = 5.2 Hz, 1 H), 6.82-6.69 (m, 2 H),
5.74 (s, 2 H), 5.34 (m, 1 H), 5.19 (m, 2 H), 5.02-4.88 (m, 1 H),
3.90 (s, 3 H), 3.60 (m, 1 H), 2.98-2.74 (m, 3 H), 2.65 (m, 1 H),
2.54 (m, 1 H), 1.31 (d, J = 6.3 Hz, 3 H), 1.27-1.22 (m, 6 H), 1.13
(d, J = 7.0 Hz, 6 H) 22 131- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. 8.53 -- 133 m/z 629.6 (d, J = 8.0 Hz, 1 H), 8.26 ([M +
H].sup.+) (d, J = 5.4 Hz, 1 H), 7.04 (dd, J = 20.7, 8.0 Hz, 4 H),
6.95 (d, J = 5.4 Hz, 1 H), 5.80-5.69 (m, 2 H), 5.36 (m, 1 H), 5.20
(m, 2 H), 4.97 (m, 1 H), 3.89 (s, 3 H), 3.59 (m, 1 H), 3.02-2.83
(m, 2 H), 2.70-2.58 (m, 2 H), 2.53 (m, 1 H), 1.31 (d, J = 6.3 Hz, 3
H), 1.24 (m, 6 H), 1.13 (d, J = 7.0 Hz, 6 H) 23 171- -- ESIMS
.sup.1H NMR (CDCl.sub.3) .delta. 8.53 -- 174 m/z 638.1 (d, J = 8.0
Hz, 1 H), 8.47 ([M + Na].sup.+) (d, J = 3.8 Hz, 1 H), 8.41 (s, 1
H), 8.27 (d, J = 5.4 Hz, 1 H), 7.48 (d, J = 7.9 Hz, 1 H), 7.21 (dd,
J = 7.8, 4.9 Hz, 1 H), 6.95 (d, J = 5.4 Hz, 1 H), 5.80- 5.65 (m, 2
H), 5.35 (m, 1 H), 5.20 (m, 2 H), 5.04- 4.90 (m, 1 H), 3.89 (s, 3
H), 3.61 (m, 1 H), 3.07- 2.83 (m, 2 H), 2.75- 2.59 (m, 2 H), 2.53
(m, 1 H), 1.32 (d, J = 6.3 Hz, 3 H), 1.25 (m, 6 H), 1.13 (d, J =
7.0 Hz, 6 H) 24 100- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. 8.53
-- 103 m/z 684.0 (d, J = 7.9 Hz, 1 H), 8.26 ([M + H].sup.+) (d, J =
5.3 Hz, 1 H), 7.52- 7.29 (m, 4 H), 6.95 (d, J = 5.4 Hz, 1H), 5.78-
5.69 (m, 2 H), 5.36 (m, 1 H), 5.20 (m, 2 H), 4.98 (m, 1 H), 3.89
(s, 3 H), 3.60 (m, 1 H), 3.07 (t, J = 12.6 Hz, 1 H), 2.99- 2.87 (m,
1 H), 2.83- 2.70 (m, 1 H), 2.63 (sept, J = 7.0 Hz, 1 H), 2.54
(sept, J = 7.0 Hz, 1 H), 1.32 (d, J = 6.3 Hz, 3 H), 1.24 (d, J =
7.0 Hz, 6 H), 1.13 (d, J = 7.0 Hz, 6 H) 25 55- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. 8.54 -- 68 m/z 691.4 (d, J = 7.9 Hz, 1 H),
8.26 ([M + H].sup.+) (d, J = 5.3 Hz, 1 H), 7.59- 7.51 (m, 2 H),
7.43 (m, 3 H), 7.34 (m, 3 H), 7.12 (d, J = 7.6 Hz, 1 H), 6.95 (d, J
= 5.4 Hz, 1 H), 5.80- 5.69 (m, 2 H), 5.38 (m, 1 H), 5.28-5.12 (m, 2
H), 4.98 (m, 1 H), 3.89 (s, 3 H), 3.60 (m, 1 H), 3.14-2.92 (m, 2
H), 2.77 (d, J = 11.9 Hz, 1 H), 2.63 (m, 1 H), 2.53 (sept, J = 7.0
Hz, 1 H), 1.32 (d, J = 6.3 Hz, 3 H), 1.24 (d, J = 7.0 Hz, 6 H),
1.13 (d, J = 7.0 Hz, 6 H) 26 68- -- ESIMS .sup.1H NMR (300 MHz, --
69 m/z 637 CDCl.sub.3) .delta. 8.60 (d, J = ([M + H].sup.+) 7.8 Hz,
1 H), 8.28 (d, J = 5.3 Hz, 1 H), 6.97 (d, J = 5.4 Hz, 1 H),
5.83-5.67 (m, 2 H), 5.48 (s, 1 H), 5.19 (d, J = 7.6 Hz, 1 H), 5.09
(t, J = 9.9 Hz, 1 H), 4.94 (dq, J = 12.4, 6.1 Hz, 1 H), 4.23-3.94
(m, 2 H), 3.91 (s, 3 H), 3.76 (s, 1 H), 2.76-2.47 (m, 3 H), 2.12
(dd, J = 15.7, 9.9 Hz, 1 H), 1.65 (s, 1 H), 1.60-1.46 (m, 1 H),
1.29 (d, J = 6.1 Hz, 3 H), 1.24-1.18 (m, 6 H), 1.16 (t, J = 6.3 Hz,
6 H), 1.02-0.91 (m, 2 H), 0.91 0.79 (m, 2 H) 27 117- -- ESIMS
.sup.1H NMR (300 MHz, -- 119 m/z 621 CDCl.sub.3) .delta. 8.60 (d, J
= ([M + H].sup.+) 7.8 Hz, 1 H), 8.29 (d, J = 5.4 Hz, 1 H), 6.97 (d,
J = 5.4 Hz, 1 H), 5.82-5.73 (m, 2 H), 5.49 (s, 1 H), 5.19 (d, J =
6.2 Hz, 1 H), 5.05 (t, J = 9.8 Hz, 1 H), 4.93 (dd, J = 9.8, 6.2 Hz,
1 H), 3.91 (s, 3 H), 3.74 (s, 1 H), 2.79-2.49 (m, 2 H), 1.82-1.55
(m, 5 H), 1.34-1.08 (m, 21 H), 1.02-0.69 (m, 3 H) 28 -- -- ESIMS
.sup.1H NMR (300 MHz, .sup.13C NMR (75 m/z 583 CDCl.sub.3) .delta.
8.60 (d, J = MHz, CDCl.sub.3) .delta. ([M + H].sup.+) 7.9 Hz, 1 H),
8.29 (d, J = 176.47, 175.80, 5.3 Hz, 1 H), 6.98 (d, J = 172.67,
170.42, 5.4 Hz, 1 H), 5.82-5.70 163.39, 160.43, (m, 2 H), 5.47 (s,
1 H), 145.83, 144.53, 5.28-5.14 (m, 1 H), 110.04, 89.85, 5.08 (q, J
= 9.9 Hz, 1 H), 75.18, 74.84, 5.01-4.87 (m, 1 H), 70.05, 65.78,
3.91 (s, 3 H), 3.77 (s, 58.80, 56.38, 1 H), 3.44-3.28 (m, 50.66,
47.31, 2 H), 3.27 (s, 3 H), 2.78 34.25, 34.04, (ddd, J = 11.6,
10.5, 5.4 28.80, 19.16, Hz, 1 H), 2.68-2.48 (m, 19.08, 18.85, 2 H),
2.04-1.91 (m, 18.01 1 H), 1.64 (ddd, J = 9.6, 8.3, 5.5 Hz, 1 H),
1.34- 1.27 (m, 3 H), 1.21 (d, J = 7.0 Hz, 6 H), 1.15 (d, J = 7.1
Hz, 6 H) 29 -- -- ESIMS .sup.1H NMR (300 MHz, .sup.13C NMR (75 m/z
659 CDCl.sub.3) .delta. 8.58 (d, J = MHz, CDCl.sub.3) .delta. ([M +
H].sup.+) 7.9 Hz, 1 H), 8.28 (d, J = 176.46, 175.82, 5.4 Hz, 1 H),
7.45-7.18 172.58, 170.51, (m, 5 H), 6.96 (d, J = 5.4 163.37,
160.45, Hz, 1 H), 5.88-5.70 (m, 145.81, 144.59, 2 H), 5.42 (s, 1
H), 5.26- 141.70, 138.31, 5.14 (m, 1 H), 5.10 (t, J = 128.50,
127.75, 9.9 Hz, 1 H), 5.00- 110.02, 89.90, 4.83 (m, 1 H), 4.43 (s,
75.22, 74.90, 2 H), 3.90 (s, 3 H), 3.69 73.09, 67.68, (s, 1 H),
3.43 (qd, J = 65.65, 56.38, 9.7, 4.4 Hz, 2 H), 2.91- 50.60, 47.53,
2.73 (m, 1 H), 2.68- 34.26, 34.06, 2.48 (m, 2 H), 2.04 (m, 28.97,
19.18, 1H), 1.64 (m, 1 H), 1.28 18.87, 18.02, (d, J = 6.2 Hz, 3 H),
1.20 14.40 (d, J = 7.0 Hz, 6 H), 1.14 (d, J = 7.0 Hz, 6 H) 30 -- --
ESIMS .sup.1H NMR (300 MHz, .sup.13C NMR (75 m/z 639 CDCl.sub.3)
.delta. 8.57 (d, J = MHz, CDCl.sub.3) .delta. ([M + H].sup.+) 8.0
Hz, 1 H), 8.28 (d, J = 176.43, 175.66, 5.4 Hz, 1 H), 6.97 (d, J =
172.14, 170.61, 5.4 Hz, 1 H), 5.80-5.69 170.40, 163.37, (m, 2 H),
5.44 (s, 1 H), 160.44, 145.78, 5.20 (dd, J = 15.3, 8.2 144.57,
141.62, Hz, 1 H), 5.04 (t, J = 9.7 110.03, 89.86, Hz, 1 H),
4.99-4.83 (m, 81.82, 74.67, 1 H), 3.90 (s, 3 H), 3.81 74.39, 65.60,
(s, 1 H), 2.97 (ddd, J = 56.37, 50.42, 12.7, 9.8, 3.1 Hz, 1 H),
46.07, 35.15, 2.80 (dd, J = 16.9, 11.7 34.20, 34.03, Hz, 1 H),
2.71-2.47 (m, 28.15, 19.13, 2 H), 2.28 (dd, J = 16.8, 19.02, 18.84,
3.1 Hz, 1 H), 1.41 (s, 17.97 9 H), 1.29 (d, J = 6.1 Hz, 3 H), 1.22
(dd, J = 7.0, 1.0 Hz, 6 H), 1.14 (d, J = 7.0 Hz, 6 H) 31 -- (Thin
ESIMS .sup.1H NMR (300 MHz, -- Film) m/z 630 CDCl.sub.3) .delta.
8.60 (d, J = 3367, ([M + H].sup.+) 7.9 Hz, 1 H), 8.51-8.43 2975,
(m, 1 H), 8.42-8.36 (m, 2938, 1 H), 8.29 (d, J = 5.4 Hz, 1754, 1
H),7.45 (d, J = 7.7 Hz, 1683, 1 H), 7.26-7.16 (m, 1506, 1 H), 6.97
(d, J = 5.4 Hz, 1470, 1 H), 5.82-5.71 (m, 1181, 2 H), 5.50 (s, 1
H), 5.20 1140, (d, J = 7.3 Hz, 1 H), 5.10
1094 (t, J = 9.9 Hz, 1 H), 4.94- 4.83 (m, 1 H), 3.91 (s, 3 H), 3.78
(s, 1 H), 2.92 (dd, J = 14.3, 6.8 Hz, 1 H), 2.70-2.43 (m, 4 H),
2.10 (s, 1 H), 1.64 (s, 1 H), 1.37 (dd, J = 6.9, 2.1 Hz, 3 H), 1.27
(d, J = 6.3 Hz, 6 H), 1.17 (dd, J = 11.0, 4.1 Hz, 6 H) 32 -- --
ESIMS .sup.1H NMR (300 MHz, .sup.13C NMR (75 m/z 629 CDCl.sub.3)
.delta. 8.60 (d, J = MHz, CDCl.sub.3) .delta. ([M + H].sup.+) 7.9
Hz, 1 H), 8.28 (d, J = 176.47, 175.67, 5.1 Hz, 1 H), 7.34-7.23
172.61, 170.45, (m, 2 H), 7.23-7.15 (m, 163.40, 160.44, 1 H),
7.14-7.06 (m, 145.81, 141.69, 2 H), 6.97 (d, J = 5.3 Hz, 140.90,
128.60, 1 H), 5.84-5.70 (m, 126.32, 110.04, 2 H), 5.50 (s, 1 H),
5.27- 106.32, 89.88, 5.15 (m, 1 H), 5.09 (t, J = 75.27, 74.80, 9.9
Hz, 1 H), 4.96- 65.76, 56.39, 4.82 (m, 1 H), 3.90 (s, 50.61, 49.54,
3 H), 3.82 (d, J = 16.2 34.27, 34.06, Hz, 1 H), 2.75-2.49 (m,
33.36, 30.46, 4 H), 2.49-2.35 (m, 19.13, 19.07, 1 H), 2.21-2.06 (m,
18.87, 17.98 1 H), 1.65 (dd, J = 17.4, 12.5 Hz, 1 H), 1.26 (d, J =
6.3 Hz, 3 H), 1.16 (t, J = 7.1 Hz, 12 H) 33 -- (Neat) ESIMS .sup.1H
NMR (CDCl.sub.3) .delta. 8.60 -- 3367, m/z 623.5 (d, J = 7.9 Hz, 1
H), 8.29 1752, ([M + H].sup.+) (d, J = 5.4 Hz, 1 H), 6.97 1682, (d,
J = 5.4 Hz, 1 H), 5.76 1505, (q, J = 6.4 Hz, 2 H), 5.49 1140 (m, 1
H), 5.18 (m, 1 H), 5.13-5.02 (m, 1 H), 4.92 (dq, J = 12.5, 6.2 Hz,
1 H), 3.90 (s, 3 H), 3.72 (m, 1 H), 2.68- 2.49 (m, 3 H), 1.72 (dd,
J = 20.5, 10.1 Hz, 1 H), 1.36-1.17 (m, 21 H), 1.15 (d, J = 7.0 Hz,
6 H), 0.86 (t, J = 6.8 Hz, 3 H) 34 -- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. 8.60 .sup.13C NMR m/z 567.5 (d, J = 7.9 Hz, 1
H), 8.29 (CDCl.sub.3) .delta. ([M + H].sup.+) (d, J = 5.4 Hz, 1 H),
6.97 176.34, 175.58, (d, J = 5.4 Hz, 1 H), 5.76 172.71, 170.30, (q,
J = 6.4 Hz, 2 H), 5.48 163.18, 160.23, (br s, 1 H), 5.19 (m, 1 H),
145.63, 144.38, 5.13-5.03 (m, 1 H), 141.45, 109.82, 4.92 (dq, J =
12.5, 6.1 89.68, 77.23, Hz, 1 H), 3.90 (s, 3 H), 75.23, 74.63, 3.73
(br s, 1 H), 2.68- 56.19, 50.49, 2.47 (m, 3 H), 1.81- 34.10, 33.86,
1.58 (m, 3 H), 1.28 (d, J = 30.51, 20.33, 6.2 Hz, 4 H), 1.21 (dd,
18.95, 18.67, J = 7.0, 1.7 Hz, 6 H), 17.80, 13.81 1.15 (d, J = 7.0
Hz, 6 H), 0.88 (t, J = 7.1 Hz, 3 H) 35 172- -- ESIMS .sup.1H NMR
(300 MHz, -- 174 m/z 522 CDCl.sub.3) .delta. 11.78 (d, J = ([M +
H].sup.+) 0.5 Hz, 1 H), 8.61 (d, J = 8.2 Hz, 1 H), 8.07-7.87 (m, 3
H), 7.65-7.53 (m, 1 H), 7.50-7.39 (m, 2 H), 6.88 (d, J = 5.1 Hz, 1
H), 5.40 (s, 1 H), 5.27- 5.08 (m, 2 H), 4.96 (dq, J = 12.5, 6.3 Hz,
1 H), 4.42-4.20 (m, 2 H), 3.95 (s, 3 H), 3.64 (s, 1 H), 2.86-2.72
(m, 1 H), 2.63 (dt, J = 14.0, 7.0 Hz, 1 H), 2.37-2.22 (m, 1 H),
1.81 (s, 1 H), 1.31 (d, J = 6.3 Hz, 3 H), 1.22 (dd, J = 7.0, 1.2
Hz, 6 H) 36 -- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. .sup.13C
NMR m/z 540 11.78 (s, 1 H), 8.66 (d, J = (CDCl.sub.3) .delta. ([M +
H].sup.+) 8.1 Hz, 1 H), 8.01 (d, J = 176.76, 175.58, 5.2 Hz, 1 H),
6.90 (d, J = 171.94, 169.75, 5.2 Hz, 1 H), 5.47 (s, 169.03, 155.45,
1 H), 5.29-5.16 (m, J = 148.85, 140.76, 7.2 Hz, 1 H), 5.10 (td, J =
129.91, 109.76, 9.9, 4.6 Hz, 1 H), 5.01- 74.90, 74.69, 4.89 (m, 1
H), 4.19- 65.11, 61.91, 3.99 (m, 2 H), 3.95 (s 56.14, 49.84, 3 H),
3.77 (s, 1 H), 2.5 47.15, 34.07, 2.67 (m, 1 H), 2.67- 33.90, 29.70,
2.57 (m, J = 13.9, 7.0 27.80, 18.91, Hz, 1 H), 2.56-2.44 (m, 18.85,
18.83, 1 H), 2.22-2.06 (m, 17.82 1 H), 1.79-1.61 (m, 1 H), 1.31 (d,
J = 6.3 Hz, 3 H), 1.22 (dd, J = 7.0, 0.8 Hz, 6 H), 1.13 (dd, J =
7.0, 0.8 Hz, 6 H) 37 -- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta.
.sup.13C NMR m/z 553 11.78 (s, 1 H), 8.65 (d, J = (CDCl.sub.3)
.delta. ([M + H].sup.+) 8.2 Hz, 1 H), 8.01 (d, J = 178.25, 175.59,
5.2 Hz, 1 H), 6.90 (d, J = 171.86, 169.77, 5.2 Hz, 1 H), 5.55-
169.02, 155.45, 5.40 (m, 1 H), 5.28- 148.85, 140.77, 5.15 (m, 1 H),
5.10 (td, J = 129.91, 109.76, 9.9, 5.2 Hz, 1 H), 5.00- 74.91,
74.70, 4.91 (m, 1 H), 4.02 (t, 65.09, 62.19, J = 6.2 Hz, 2 H), 3.95
(s, 56.14, 49.80, 3 H), 3.76 (s, 1 H), 2.76- 47.27, 38.71, 2.67 (m,
1 H), 2.62 (dq, 34.08, 29.70, J = 14.0, 7.0 Hz, 1 H), 27.80, 27.05,
2.24-2.00 (m, 1 H), 18.92, 18.89, 1.72 (m, 1 H), 1.31 (d, J = 17.82
6.3 Hz, 3 H), 1.22 (dd, J = 7.0, 1.1 Hz, 6 H), 1.16 (s, 9 H) 38
157- -- ESIMS .sup.1H NMR (300 MHz, -- 159 m/z 537 CDCl.sub.3)
.delta. 11.79 (s, 1 H), ([M + H].sup.+) 8.65 (d, J = 8.2 Hz, 1 H),
8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.48 (s, 1
H), 5.21 (d, J = 7.3 Hz, 1 H), 5.10 (t, J = 9.9 Hz, 1 H), 5.04-4.89
(m, 1 H), 4.22-4.06 (m, 1 H), 4.06-3.99 (m, 1 H), 3.95 (s, 3 H),
3.78 (s, 1 H), 2.79-2.67 (m, 1 H), 2.63 (dt, J = 14.0, 7.0 Hz, 1
H), 2.13 (s, 1 H), 1.71 (s, 1 H), 1.54 (m, 1 H), 1.30 (d, J = 6.2
Hz, 3 H), 1.22 (dd, J = 7.0, 0.5 Hz, 6 H), 1.02- 0.92 (m, 2 H),
0.89- 0.80 (m, 2 H) 39 159- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. -- 161 m/z 617 11.78 (s, 1 H), 8.62 (d, J = ([M + H].sup.+)
8.2 Hz, 1 H), 8.00 (d, J = 5.2 Hz, 1 H), 7.58 (dd, J = 8.2, 1.6 Hz,
1 H), 7.39 (d, J = 1.5 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 6.84
(d, J = 8.2 Hz, 1 H), 6.04 (s, 2 H), 5.42 (s, 1 H), 5.21 (d, J =
6.9 Hz, 1 H), 5.13 (t, J = 9.9 Hz, 1 H), 4.96 (dq, J = 12.4, 6.2
Hz, 1 H), 4.35-4.18 (m, 2 H), 3.95 (s, 3 H), 3.68 (s, 1 H), 2.76
(t, J = 9.6 Hz, 1 H), 2.63 (dt, J = 14.0, 7.0 Hz, 1 H), 2.28 (d, J
= 6.7 Hz, 1 H), 1.86-1.73 (m, 1 H), 1.31 (d, J = 6.3 Hz, 3 H), 1.22
(dd, J = 7.0, 1.1 Hz, 6 H) 40 178- -- ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. -- 179 m/z 649 11.77 (s, 1 H), 8.61 (d, J =
([M + H].sup.+) 8.2 Hz, 1 H), 8.07- 8.01 (m, 2 H), 7.99 (d, J = 5.2
Hz, 1 H), 7.70- 7.65 (m, 2 H), 7.65- 7.60 (m, 2 H), 7.51- 7.44 (m,
2 H), 7.42- 7.36 (m, 1 H), 6.88 (d, J = 5.2 Hz, 1 H), 5.43 (s, 1
H), 5.28-5.10 (m, 2 H), 4.97 (dq, J = 12.6, 6.2 Hz, 1 H), 4.37
(ddd, J = 11.9, 7.0, 5.2 Hz, 1 H), 4.28 (dt, J = 14.8, 6.2 Hz, 1
H), 3.94 (s, 3 H), 3.67 (s, 1 H), 2.87- 2.74 (m, 1 H), 2.70- 2.57
(m, 1 H), 2.41- 2.24 (m, 1 H), 1.91- 1.76 (m, 1 H), 1.32 (d, J =
6.3 Hz, 3 H), 1.23 (dd, J = 7.0, 2.2 Hz, 6 H) 41 -- -- ESIMS
.sup.1H NMR (CDCl.sub.3) .delta. -- m/z 663 11.76 (s, 1 H), 8.62
(d, J = ([M + H].sup.+) 8.1 Hz, 1 H), 8.00 (d, J = 5.2 Hz, 1 H),
7.25 (s, 2 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.38 (s, 1 H), 5.25- 5.09
(m, 2 H), 4.98 (dq, J = 12.5, 6.3 Hz, 1 H), 4.34 (ddd, J = 12.1,
7.0, 5.5 Hz, 1 H), 4.30-4.20 (m, 1 H), 3.94 (s, 3 H), 3.92 (s, 6
H), 3.91 (s, 3 H), 3.75-3.60 (m, 1 H), 2.79-2.69 (m, 1 H),
2.68-2.59 (m, 1 H), 2.37-2.24 (m, 1 H), 1.87-1.72 (m, 1 H), 1.31
(d, J = 6.3 Hz, 3 H), 1.23 (dd, J = 7.0, 1.8 Hz, 6 H) 42 160- --
ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 162 m/z 641 11.84-11.70
(m, 1 H), ([M + H].sup.+) 8.63 (d, J = 8.2 Hz, 1 H), 8.09 (d, J =
8.1 Hz, 2 H), 8.00 (d, J = 5.2 Hz, 1 H), 7.72 (d, J = 8.2 Hz, 2 H),
6.89 (d, J = 5.2 Hz, 1 H), 5.41 (s, 1 H), 5.28-5.10 (m, 2 H),
5.03-4.91 (m, 1 H), 4.45-4.24 (m, 2 H), 3.95 (s, 3 H), 3.70 (s, 1
H), 2.78 (td, J = 11.5, 2.5 Hz, 1 H), 2.64 (hept, J = 7.0 Hz, 1 H),
2.32 (ddd, J = 17.8, 11.5, 5.2 Hz, 1 H), 1.91- 1.79 (m, 1 H), 1.32
(dd, J = 6.2, 2.4 Hz, 3 H), 1.22 (dd, J = 7.0, 1.1 Hz, 6 H) 43 167-
-- ESIMS .sup.1H NMR (300 MHz, -- 168 m/z 663 CDCl.sub.3) .delta.
11.76 (s, 1 H), ([M + H].sup.+) 8.64 (d, J = 8.2 Hz, 1 H), 7.99 (d,
J = 5.2 Hz, 1 H), 6.90 (d, J = 5.2 Hz, 1 H), 5.44 (s, 1 H), 5.21
(dd, J = 15.5, 8.1 Hz, 1 H), 5.12 (t, J = 9.8 Hz, 1 H), 4.96 (dq, J
= 12.3, 6.1 Hz, 1 H), 4.44 (dt, J = 10.6, 5.2 Hz, 1 H), 4.36- 4.21
(m, 1 H), 3.95 (s, 3 H), 3.75 (d, J = 25.0 Hz, 1 H), 2.89-2.75 (m,
1 H), 2.71-2.55 (m, 1 H), 2.29-2.12 (m, 1 H), 1.86 (d, J = 14.7 Hz,
1 H), 1.32 (d, J = 6.2 Hz, 3 H), 1.22 (d, J = 7.0 Hz, 6 H) 44 128-
-- ESIMS .sup.1H NMR (300 MHz, -- 130 m/z 439 CDCl.sub.3) .delta.
11.81 (s, 1 H), ([M + H].sup.+) 8.67 (d, J = 8.3 Hz, 1 H), 8.01
(dd, J = 5.2, 0.5 Hz, 2 H), 6.90 (d, J = 5.2 Hz, 2 H), 5.62-5.37
(m, 1 H), 5.30-5.16 (m, J =
14.9, 8.1 Hz, 2 H), 5.09 (q, J = 9.5 Hz, 2 H), 5.02- 4.89 (m, 2 H),
3.95 (s, 3 H), 3.81 (s, 1 H), 3.45- 3.29 (m, 2 H), 3.27 (s, 2 H),
2.85-2.72 (m, 1 H), 2.62 (ddd, J = 11.8, 8.1, 5.9 Hz, 1 H), 2.08-
1.92 (m, 2 H), 1.84- 1.57 (m, 2 H), 1.30 (d, J = 6.2 Hz, 3 H), 1.22
(d, J = 7.0 Hz, 6 H) 45 134- -- ESIMS .sup.1H NMR (300 MHz, -- 136
m/z 497 CDCl.sub.3) .delta. 11.81 (s, 1 H), ([M + H].sup.+) 8.66
(d, J = 8.0 Hz, 1 H), 8.01 (d, J = 5.1 Hz, 1 H), 6.89 (d, J = 5.2
Hz, 1 H), 5.48 (s, 1 H), 5.20 (d, J = 6.8 Hz, 1 H), 5.11 (t, J =
9.9 Hz, 1 H), 5.03-4.89 (m, 1 H), 3.95 (s, 3 H), 3.78 (s, 1 H),
3.46-3.32 (m, 4 H), 2.84-2.69 (m, 1 H), 2.69-2.55 (m, 1 H), 2.01
(dt, J = 11.3, 4.8 Hz, 1 H), 1.61 (m, 1 H), 1.30 (d, J = 6.2 Hz, 3
H), 1.21 (d, J = 7.0 Hz, 6 H), 1.13 (t, J = 7.0 Hz, 3 H) 46 198- --
ESIMS .sup.1H NMR (300 MHz, -- 200 m/z 439 CDCl.sub.3) .delta.
11.80 (s, 1 H), ([M + H].sup.+) 8.65 (d, J = 7.9 Hz, 1 H), 8.01 (d,
J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.54-5.31 (m, 1 H),
5.19 (dd, J = 15.3, 8.1 Hz, 1 H), 5.04 (t, J = 9.7 Hz, 1 H), 4.94
(td, J = 12.2, 6.1 Hz, 1 H), 3.95 (s, 3 H), 3.78 (s, 1 H), 2.65
(ddt, J = 20.9, 13.8, 6.8 Hz, 2 H), 1.30 (d, J = 6.1 Hz, 3 H), 1.22
(d, J = 7.0 Hz, 6 H), 1.16 (d, J = 6.7 Hz, 3H) 47 192- -- ESIMS
.sup.1H NMR (400 MHz, .sup.13C NMR (101 194 m/z 539 CDCl.sub.3)
.delta. 11.79 (d, J = MHz, CDCl.sub.3) .delta. ([M + H].sup.+) 0.5
Hz, 1 H), 8.63 (d, J = 175.50, 172.00, 8.3 Hz, 1 H), 8.01 (d, J =
170.26, 169.90, 5.2 Hz, 1 H), 6.89 (d, J = 169.01, 155.45, 5.1 Hz,
1 H), 5.45 (s, 148.86, 140.73, 1 H), 5.21 (dd, J = 15.5, 129.97,
109.74, 8.3 Hz, 1 H), 5.12-5.01 81.74, 74.79, (m, 1 H), 5.01-4.87
(m, 74.07, 65.03, 1 H), 3.95 (s, 3 H), 3.80 56.13, 49.80, (d, J =
25.0 Hz, 1 H), 45.81, 34.93, 2.98 (ddd, J = 11.8, 9.9, 34.02,
27.97, 3.2 Hz, 1 H), 2.86-2.74 18.96, 18.84, (m, 1 H), 2.62 (dt, J
= 17.79 14.0, 7.0 Hz, 1 H), 2.35- 2.23 (m, 1 H), 1.41 (s, 9 H),
1.30 (dd, J = 6.2, 2.4 Hz, 3 H), 1.22 (dd, J = 7.0, 1.6 Hz, 6 H) 48
176- -- ESIMS .sup.1H NMR (300 MHz, -- 178 m/z 559 CDCl.sub.3)
.delta. 11.77 (s, 1 H), ([M + H].sup.+) 8.62 (d, J = 8.4 Hz, 1 H),
8.01 (d, J = 5.2 Hz, 1 H), 7.36 (t, J = 7.7 Hz, 2 H), 7.26-7.16 (m,
1 H), 7.12-6.98 (m, 2 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.44 (s, 1 H),
5.19 (dt, J = 18.7, 8.6 Hz, 2 H), 5.05-4.92 (m, 1 H), 3.95 (s, 3
H), 3.82 (s, 1 H), 3.23-3.07 (m, 2 H), 2.65 (dd, J = 13.2, 6.2 Hz,
2 H), 1.33 (d, J = 6.2 Hz, 3 H), 1.25 (dd, J = 7.0, 1.4 Hz, 6 H) 49
169- -- ESIMS .sup.1H NMR (300 MHz, -- 170 m/z 525 CDCl.sub.3)
.delta. 11.79 (s, 1 H), ([M + H].sup.+) 8.63 (d, J = 8.4 Hz, 1 H),
8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.57-5.32 (m,
1 H), 5.21 (dd, J = 15.6, 8.3 Hz, 1 H), 5.07 (t, J = 9.8 Hz, 1 H),
4.97 (dt, J = 16.2, 5.6 Hz, 2 H), 3.95 (s, 3 H), 3.83 (s, 1 H),
3.09-2.95 (m, 1 H), 2.85 (dd, J = 17.1, 11.7 Hz, 1 H), 2.62 (dt, J
= 14.0, 7.0 Hz, 1 H), 2.34 (dd, J = 17.1, 3.1 Hz, 1 H), 1.30 (d, J
= 6.1 Hz, 3 H), 1.27-1.14 (m, 12 H) 50 138- -- ESIMS .sup.1H NMR
(300 MHz, -- 140 m/z 497 CDCl.sub.3) .delta. 11.74 (s, 1 H), ([M +
H].sup.+) 8.67-8.52 (m, 1 H), 8.05-7.76 (m, 1 H), 6.85 (d, J = 5.2
Hz, 1 H), 5.53-5.28 (m, 1 H), 5.26-5.11 (m, 1 H), 5.03 (t, J = 9.8
Hz, 1 H), 4.98-4.84 (m, 1 H), 3.91 (s, 3 H), 3.88-3.75 (m, 1 H),
3.63 (s, 3 H), 3.03 (ddd, J = 11.6, 7.6, 3.2 Hz, 1 H), 2.92-2.79
(m, 1 H), 2.65-2.50 (m, 1 H), 2.43-2.30 (m, 1 H), 1.32-1.23 (m, 3
H), 1.18 (d, J = 7.0 Hz, 6 H) 51 103- -- ESIMS .sup.1H NMR (300
MHz, -- 105 m/z 497 CDCl.sub.3) .delta. 11.78 (s, 1 H), ([M +
H].sup.+) 8.64 (d, J = 7.9 Hz, 1 H), 8.09-7.92 (m, 2 H), 6.90 (d, J
= 5.3 Hz, 1 H), 5.47 (s, 1 H), 5.21 (d, J = 7.0 Hz, 1 H), 5.11 (t,
J = 9.9 Hz, 1 H), 5.01-4.88 (m, 1 H), 4.21 (dt, J = 11.0, 5.4 Hz, 1
H), 4.14- 4.00 (m, 1 H), 3.95 (s, 3 H), 3.79 (s, 1 H), 2.84- 2.69
(m, 1 H), 2.63 (dt, J = 14.0, 7.0 Hz, 1 H), 2.20-2.06 (m, 1 H),
1.78 (s, 1 H), 1.31 (d, J = 6.2 Hz, 3 H), 1.22 (d, J = 7.0 Hz, 6 H)
52 195- -- ESIMS .sup.1H NMR (300 MHz, -- 196 m/z 489 CDCl.sub.3)
.delta. 11.76 (s, 1 H), ([M + H].sup.+) 8.64 (d, J = 8.1 Hz, 1 H),
8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 6.06-5.60 (m,
1 H), 5.45 (s, 1 H), 5.22 (dd, J = 15.5, 8.1 Hz, 1 H), 5.09 (t, J =
9.8 Hz, 1 H), 5.03-4.90 (m, 1 H), 3.95 (s, 3 H), 3.81 (s, 1 H),
2.94-2.80 (m, 1 H), 2.64 (dt, J = 14.0, 7.0 Hz, 1 H), 2.58-2.33 (m,
1 H), 1.92-1.72 (m, 1 H), 1.32 (d, J = 6.2 Hz, 3 H), 1.23 (dd, J =
9.6, 2.8 Hz, 6 H) 53 193- -- ESIMS .sup.1H NMR (300 MHz, -- 195 m/z
453 CDCl.sub.3) .delta. 11.81 (s, 1 H), ([M + H].sup.+) 8.66 (d, J
= 8.1 Hz, 1 H), 8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1
H), 5.47 (s, 1 H), 5.20 (dd, J = 14.7, 8.1 Hz, 1 H), 5.08 (t, J =
9.9 Hz, 1 H), 4.93 (dq, J = 9.7, 6.3 Hz, 1 H), 3.95 (s, 3 H), 3.78
(m, 1 H), 2.70- 2.57 (m, 1 H), 2.52 (ddd, J = 11.5, 7.4, 2.5 Hz, 1
H), 1.81-1.63 (m, 2 H), 1.53-1.34 (m, 2 H), 1.29 (d, J = 6.2 Hz, 3
H), 1.21 (d, 6 H), 0.88 (t, J = 7.4 Hz, 3 H) 54 222- -- ESIMS
.sup.1H NMR (300 MHz, -- 224 m/z 631 CDCl.sub.3) .delta. 11.75 (s,
1 H), ([M + H].sup.+) 8.64 (d, J = 8.1 Hz, 1 H), 8.01 (d, J = 5.2
Hz, 1 H), 7.82 (s, 1 H), 7.70 (d, J = 7.6 Hz, 2 H), 7.36 (dd, J =
13.8, 6.4 Hz, 2 H), 6.90 (d, J = 5.2 Hz, 1 H), 5.46 (s, 1 H), 5.21
(d, J = 8.1 Hz, 1 H), 5.12 (t, J = 9.7 Hz, 1 H), 4.96-4.86 (m, 1
H), 4.51-4.31 (m, 2 H), 3.96 (s, 3 H), 3.89- 3.76 (m, 1 H), 2.75-
2.54 (m, 2 H), 2.37 (s, 1 H), 2.14 (s, 1 H), 1.30 (d, J = 6.2 Hz, 3
H), 1.20 (d, J = 7.0 Hz, 6 H) 55 222- -- ESIMS .sup.1H NMR (300
MHz, -- 224 m/z 596 CDCl.sub.3) .delta. 11.76 (s, 1 H), ([M +
H].sup.+) 8.64 (d, J = 8.2 Hz, 1 H), 8.01 (d, J = 5.2 Hz, 1 H),
7.89-7.77 (m, 2 H), 7.70 (s, 1 H), 7.51-7.30 (m, 3 H), 6.89 (d, J =
5.2 Hz, 1 H), 5.46 (s, 1 H), 5.32-5.18 (m, 1 H), 5.12 (t, J = 9.8
Hz, 1 H), 4.90 (dq, J = 12.6, 6.3 Hz, 1 H), 4.50-4.26 (m, 2 H),
3.95 (s, 3 H), 3.81 (s, 1 H), 2.75-2.51 (m, 2 H), 2.36 (dd, J =
16.7, 9.0 Hz, 1 H), 2.12 (s, 1 H), 1.30 (d, J = 6.3 Hz, 3 H), 1.19
(d, J = 7.0 Hz, 6 H) 56 153- -- ESIMS .sup.1H NMR (CDCl.sub.3)
.delta. -- 155 m/z 547 11.76 (d, J = 0.5 Hz, ([M + H].sup.+) 1 H),
8.65 (d, J = 8.1 Hz, 1 H), 8.02 (d, J = 5.2 Hz, 1 H), 6.90 (d, J =
5.2 Hz, 1 H), 5.47 (s, 1 H), 5.20 (dd, J = 15.2, 7.8 Hz, 1 H),
5.16-5.05 (m, 1 H), 4.96 (dq, J = 9.8, 6.2 Hz, 1 H), 4.28 (dt, J =
10.5, 5.3 Hz, 1 H), 4.20-4.07 (m, 1 H), 3.95 (s, 3 H), 3.78 (d, J =
12.1 Hz, 1 H), 2.98 (d, J = 1.4 Hz, 3 H), 2.89- 2.82 (m, 1 H), 2.63
(hept, J = 7.0 Hz, 1 H), 2.24-2.10 (m, J = 11.2, 4.7 Hz, 1 H),
1.94-1.79 (m, J = 8.6, 5.8 Hz, 1 H), 1.35-1.28 (m, 3 H), 1.22 (dd,
J = 7.0, 0.9 Hz, 6 H) 57 183- -- ESIMS .sup.1H NMR (300 MHz, -- 184
m/z 529 CDCl.sub.3) .delta. 11.80 (s, 1 H), ([M + H].sup.+) 8.66
(d, J = 8.1 Hz, 1 H), 8.01 (d, J = 5.2 Hz, 1 H), 7.34-7.15 (m, 3
H), 7.15-7.02 (m, 2 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.50 (s, 1 H),
5.21 (dd, J = 15.1, 7.6 Hz, 1 H), 5.10 (t, J = 9.9 Hz, 1 H),
4.96-4.83 (m, 1 H), 3.95 (s, 3 H), 3.80 (s, 1 H), 2.78-2.51 (m, 3
H), 2.51-2.35 (m, 1 H), 2.21-2.06 (m, 1 H), 1.73-1.58 (m, 1 H),
1.28 (d, J = 6.2 Hz, 3 H), 1.18 (d, J = 7.0 Hz,
6 H) 58 142- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 144 m/z
547 11.88-11.72 (m, 1 H), ([M + H].sup.+) 8.66 (d, J = 8.1 Hz, 1
H), 8.01 (dd, J = 5.2, 1.0 Hz, 1 H), 7.13-7.02 (m, 1 H), 7.02-6.92
(m, 1 H), 6.90 (d, J = 5.2 Hz, 1 H), 5.49 (s, 1 H), 5.21 (d, J =
6.0 Hz, 1 H), 5.15- 5.02 (m, 1H), 5.02 - 4.86 (m, 1 H), 3.95 (d, J
= 1.0 Hz, 3 H), 3.78 (d, J = 11.6 Hz, 1 H),2.76- 2.47 (m, 3 H),
2.47- 2.33 (m, 1 H), 2.17- 2.01 (m, 1 H), 1.79- 1.70 (m, 1 H),
1.65- 1.53 (m, 1 H), 1.50- 1.36 (m, 1 H), 1.31- 1.26 (m, 3 H),
1.23- 1.15 (m, 6 H) 59 169- -- ESIMS .sup.1H NMR (300 MHz, -- 170
m/z 530 CDCl.sub.3) .delta. 11.79 (s, 1 H), ([M + H].sup.+) 8.66
(d, J = 8.2 Hz, 1 H), 8.46 (dd, J = 4.8, 1.6 Hz, 1 H), 8.40 (d, J =
1.7 Hz, 1 H), 8.02 (d, J = 5.2 Hz, 1 H), 7.51-7.39 (m, 1 H),
7.26-7.17 (m, 1 H), 6.90 (d, J = 5.2 Hz, 1 H), 5.50 (s, 1 H), 5.21
(dd, J = 15.1, 8.2 Hz, 1 H), 5.11 (t, J = 9.9 Hz, 1 H), 4.91 (dq, J
= 12.6, 6.3 Hz, 1 H), 3.96 (s, 3 H), 3.81 (s, 1 H), 2.76- 2.37 (m,
3 H), 2.25- 2.04 (m, 1 H), 1.81- 1.56 (m, 2 H), 1.28 (d, J = 6.3
Hz, 3 H), 1.18 (dd, J = 7.0, 1.3 Hz, 6 H) 60 139- -- ESIMS .sup.1H
NMR (300 MHz, -- 140 m/z 559 CDCl.sub.3) .delta. 11.81 (s, 1 H),
([M + H].sup.+) 8.65 (d, J = 8.3 Hz, 1 H), 8.01 (d, J = 5.2 Hz, 1
H), 7.40-7.23 (m, 5 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.50-5.30 (m, 1
H), 5.28-5.05 (m, 2 H), 5.03-4.87 (m, 1 H), 4.44 (s, 2 H), 3.95 (s,
3 H), 3.71 (s, 1 H), 3.57- 3.34 (m, 2 H), 2.83 (td, J = 11.5, 2.8
Hz, 1 H), 2.61 (hept, J = 7.0 Hz, 1 H), 2.15-1.98 (m, 1 H),
1.78-1.56 (m, 1 H), 1.29 (d, J = 6.2 Hz, 3 H), 1.21 (d, J = 7.0 Hz,
6 H) 61 188- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 189 m/z
521 11.80 (s, 1 H), 8.58 (t, J = ([M + H].sup.+) 42.0 Hz, 1 H),
8.01 (d, J = 5.2 Hz, 1 H), 6.88 (d, J = 5.2 Hz, 1 H), 5.48 (s, 1
H), 5.18 (d, J = 6.9 Hz, 1 H), 5.05 (td, J = 9.9, 5.8 Hz, 1 H),
5.00-4.84 (m, 1 H), 3.95 (s, 3 H), 3.76 (s, 1 H), 2.76-2.66 (m, 1
H), 2.65-2.54 (m, 1 H), 1.83-1.58 (m, 7 H), 1.29 (dd, J = 6.2, 2.5
Hz, 3 H), 1.21 (dd, J = 7.0, 3.1 Hz, 6 H), 1.13 (m, J = 31.1, 15.2,
7.8 Hz, 6 H) 62 -- -- -- .sup.1H NMR (CDCl.sub.3) .delta. .sup.13C
NMR 11.80 (s, 1 H), 8.61 (t, J = (CDCl.sub.3) .delta. 25.3 Hz, 1
H), 8.00 (d, 175.54, 172.69, J = 5.2 Hz, 1 H), 6.88 (d, 169.75,
169.02, J = 5.2 Hz, 1 H), 5.40 (d, 155.47, 148.89, J = 45.6 Hz, 1
H), 5.18 140.70, 130.04, (dd, J = 14.8, 7.9 Hz, 109.74, 75.29, 1
H), 5.08 (td, J = 9.9, 74.90, 65.08, 4.8 Hz, 1 H), 4.93 (dq, J =
56.11, 50.34, 9.8, 6.2 Hz, 1 H), 3.95 50.08, 37.33, (s, 3 H), 3.77
(d, J = 6.4 34.67, 34.14, Hz, 1 H), 2.62 (dq, J = 33.27, 32.89,
14.0, 7.0 Hz, 1 H), 2.57- 26.55, 26.24, 2.46 (m, 1 H), 1.69 (m,
26.17, 25.82, 8 H), 1.30 (d, J = 9.5 Hz, 18.98, 18.91, 3 H), 1.22
(dd, J = 7.0, 17.78 2.3 Hz, 6 H), 1.19-0.97 (m, 6 H) 63 131- --
ESIMS .sup.1H NMR (CDCl.sub.3) .delta. -- 134 m/z 523.4 11.81 (s, 1
H), 8.66 (d, J = ([M + H].sup.+) 8.1 Hz, 1 H), 8.01 (d, J = 5.2 Hz,
1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.19 (m, 1 H), 5.14-5.02 (m, 1 H),
5.02-4.87 (m, 1 H), 3.95 (s, 3 H), 3.87- 3.69 (m, 1 H), 2.70- 2.52
(m, 2 H), 1.80- 1.66 (m, 1 H), 1.43- 1.08 (m, 21 H), 0.86 (t, J =
6.8 Hz, 3 H) 64 165- -- ESIMS .sup.1H NMR (CDCl.sub.3) .delta. --
168 m/z 467.3 11.81 (s, 1 H), 8.66 (d, J = ([M + H].sup.+) 8.1 Hz,
1 H), 8.01 (d, J = 5.2 Hz, 1 H), 6.89 (d, J = 5.2 Hz, 1 H), 5.47
(br s, 1 H), 5.19 (dd, J = 14.9, 7.6 Hz, 1 H), 5.08 (t, J = 9.9 Hz,
1 H), 4.94 (dq, J = 9.8, 6.2 Hz, 1 H), 3.95 (s, 3 H), 3.85- 3.69
(m, 1 H), 2.68- 2.53 (m, 2 H), 1.83- 1.69 (m, 1 H), 1.29 (d, J =
6.3 Hz, 3 H), 1.40- 1.10 (m, 3 H); 1.22 (dd, J = 7.0, 1.8 Hz, 6 H),
0.88 (t, J = 7.1 Hz, 3 H) 65 148- (Neat) ESIMS .sup.1H NMR
(CDCl.sub.3) .delta. .sup.13C NMR 150 3356, m/z 548 11.81 (s, 1 H),
8.61 (d, J = (CDCl.sub.3) .delta. 2976, ([M + H].sup.+) 8.4 Hz, 1
H), 8.41- 176.21, 172.00, 2943, 8.36 (m, 1 H), 8.01 (d, J = 170.30,
169.38, 1742, 5.2 Hz, 1 H), 7.51- 157.47, 155.81, 1653 7.44 (m, 1
H), 7.17- 149.78, 149.19, 7.12 (m, 1 H), 7.01 (ddd, 141.19, 136.46,
J = 7.2, 4.9, 1.0 Hz, 130.27, 122.94, 1 H), 6.90 (d, J = 5.2 Hz,
120.20, 110.13, 1 H), 5.50 (bs, 1 H), 5.29- 75.08, 65.47, 5.13 (m,
2 H), 4.97 56.59, 51.20, (dd, J = 9.8, 6.2 Hz, 50.09, 39.06, 1 H),
3.97 (s, 3 H), 3.68 34.70, 28.67, (m, 2 H), 3.16 (t, J = 9.4 19.45,
19.28, Hz, 2 H), 2.73 (dt, J = 18.19 14.0, 7.1 Hz, 1 H), 1.38- 1.28
(m, 9 H) 66 164- -- HRMS-ESI .sup.1H NMR (CDCl.sub.3) .delta. 8.70
-- 170 (m/z) (d, J = 7.5 Hz, 1 H), 8.35 calcd for (d, J = 5.4 Hz, 1
H), 7.03 C.sub.28H.sub.38N.sub.2O.sub.10, (d, J = 5.5 Hz, 1 H),
5.47 562.2526; (br s, 1 H), 5.25-5.11 found, (m, 1 H), 5.03 (t, J =
9.9 562.2516 Hz, 1 H), 4.97-4.84 (m, 1 H), 3.92 (s, 3 H), 3.72 (br
s, 1 H), 2.69 (dd, J = 16.8, 7.0 Hz, 1 H), 2.60 (sept, J = 14.0,
7.0 Hz, 1 H), 2.40 (s, 3 H), 1.83- 1.54 (m, 6 H), 1.36- 1.02 (m, 14
H), 0.94- 0.67 (m, 2 H) 67 127- -- HRMS-ESI .sup.1H NMR
(CDCl.sub.3) .delta. 8.64 -- 134 (m/z) (d, J = 8.0 Hz, 1 H), 8.33
calcd for (d, J = 5.4 Hz, 1 H), 7.52
C.sub.29H.sub.31F.sub.3N.sub.2O.sub.10, (d, J = 8.1 Hz, 2 H), 7.24
624.1931; (d, J = 8.1 Hz, 2 H), 7.01 found, (d, J = 5.5 Hz, 1 H),
5.33 624.1954 (br s, 1 H), 5.26-5.11 (m, 2 H), 4.97 (dq, J = 12.2,
6.1 Hz, 1 H), 3.91 (s, 3 H), 3.58 (br s, 1 H), 3.05 (t, J = 12.5
Hz, 1 H), 2.98-2.87 (m, 1 H), 2.74 (d, J = 12.5 Hz, 1 H), 2.63 (td,
J = 13.9, 6.9 Hz, 1 H), 2.38 (s, 3 H), 1.31 (d, J = 6.3 Hz, 3 H),
1.24 (d, J = 7.0 Hz, 6 H) 68 199- -- HRMS-ESI .sup.1H NMR
(CDCl.sub.3) .delta. 8.68 -- 200 (m/z) (d, J = 7.8 Hz, 1 H), 8.34
calcd for (d, J = 5.4 Hz, 1 H), 8.08
C.sub.31H.sub.33F.sub.3N.sub.2O.sub.12, (d, J = 8.1 Hz, 2 H), 7.72
682.1986; (d, J = 8.2 Hz, 2 H), 7.03 found, (d, J = 5.5 Hz, 1 H),
5.40 682.2022 (br s, 1 H), 5.26-5.06 (m, 2 H), 4.95 (dq, J = 12.5,
6.2 Hz, 1 H), 4.43- 4.25 (m, 2 H), 3.91 (s, 3 H), 3.64 (br s, 1 H),
2.82-2.71 (m, 1 H), 2.68-2.58 (m, 1 H), 2.40 (s, 3 H), 2.37-2.23
(m, 1 H), 1.88-1.76 (m, 1 H), 1.29 (d, J = 6.3 Hz, 3 H), 1.22 (dd,
J = 7.0, 0.9 Hz, 6 H) 69 158- -- HRMS-ESI .sup.1H NMR (CDCl.sub.3)
.delta. 8.71 -- 161 (m/z) (d, J = 7.8 Hz, 1 H), 8.35 calcd for (d,
J = 5.4 Hz, 1 H), 7.03 C.sub.23H.sub.30N.sub.2O.sub.10, (d, J = 5.5
Hz, 1 H), 5.46 494.1900; (br s, 1 H), 5.18 (dd, J = found, 14.7,
7.7 Hz, 1 H), 5.11- 494.1919 5.00 (m, 1 H), 4.98- 4.85 (m, 1 H),
3.92 (s, 3 H), 3.73 (br s, 1 H), 2.60 (dt, J = 14.0, 7.0 Hz, 1 H),
2.55-2.45 (m, 1 H), 2.40 (s, 3 H), 1.71 (ddd, J = 13.2, 11.7, 7.2
Hz, 1 H), 1.41 (m, 1 H), 1.27 (d, J = 6.3 Hz, 3 H), 1.21 (d, J =
7.0 Hz, 6 H), 0.87 (t, J = 7.4 Hz, 3 H) 70 151- -- HRMS-ESI .sup.1H
NMR (CDCl.sub.3) .delta. 8.64 -- 160 (m/z) (d, J = 8.0 Hz, 1 H),
8.46 calcd for (d, J = 3.4 Hz, 1 H), 8.41
C.sub.27H.sub.31N.sub.3O.sub.10, (s, 1 H), 8.33 (d, J = 5.4
557.2009; Hz, 1 H), 7.52-7.43 (m, found, 1 H), 7.20 (dd, J = 7.8,
557.2015 4.8 Hz, 1 H), 7.01 (d, J = 5.5 Hz, 1 H), 5.33 (br s, 1 H),
5.19 (m, J = 18.9, 9.1 Hz, 2 H), 5.08-4.88 (m, 1 H), 3.91 (s, 3 H),
3.59 (br s, 1 H), 3.06- 2.83 (m, 2 H), 2.75- 2.60 (m, 2 H), 2.39
(s, 3 H), 1.31 (d, J = 6.3 Hz, 3 H), 1.25 (dd, J = 7.0, 2.0 Hz, 6
H) *.sup.1H NMR were recorded at 400 MHz unless noted otherwise.
*.sup.13C NMR were recorded at 101 MHz unless noted otherwise.
TABLE-US-00003 TABLE 3 Biological Testing Rating Scale PUCCRT* and
SEPTTR* Rating Table % Control Rating 50-100 A More than 0-Less
than 50 B Not Tested C No activity noticed in this bioassay D
*PUCCRT--Wheat Brown Rust (Puccinia triticina) *SEPTTR--Wheat Leaf
Blotch (Septoria tritici)
TABLE-US-00004 TABLE 4 Biological Activity-Disease Control at 100
ppm Compound PUCCRT* SEPTTR* Number 1 DP* 3 DC* 1 DP 3 DC 1 A B A B
2 A A A A 3 A A A A 4 A B A B 5 A A A A 6 A D A B 7 A A B B 8 A A A
B 9 A A A B 10 A A A B 11 A A A B 12 A B A B 13 A B A B 14 A A B B
15 A B A B 16 A B A B 17 A A A B 18 A D A B 19 A A A B 20 A A A A
21 A A A A 22 A A B B 23 A A B B 24 A A A B 25 A A A B 26 A A B B
27 B B B B 28 A A A A 29 A A A B 30 A A A A 31 A B B B 32 A A A A
33 A A A A 34 A A A A 35 A D A D 36 A D A B 37 A B A B 38 A D A B
39 A B A B 40 A D A B 41 A D B B 42 A D B B 43 A B A B 44 A A A A
45 A A B B 46 A B A D 47 A A A A 48 A D A B 49 A A A A 50 A A A A
51 A D B B 52 A B A B 53 A D A B 54 A D A B 55 A B A B 56 A B B B
57 A A A B 58 A A A B 59 A B B B 60 A A A B 61 A B A A 62 A B A B
63 A D A B 64 A B A A 65 A B A B 66 A A A A 67 A A B D 68 B B B B
69 A A A A 70 A A B B *PUCCRT--Wheat Brown Rust (Puccinia
triticina) *SEPTTR--Wheat Leaf Blotch (Septoria tritici) *1 DP--1
Day Protectant *3 DC--3 Day Curative
* * * * *